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The development of recombinant-based liquid fibrin tissue sealants having enhanced 
hemostatic and wound healing properties will involve understanding as yet not well 
characterized  interactions between fibrinogen, fibrin (Fbn) factor XIII, thrombin and fibronectin.  
We study these phenomena in the context of comparing plasma derived fibrinogen to 
recombinant fibrinogen (rFI) produced in the milk of transgenic cows. An abundance of purified 
γγ and γγ’ FI subspecies enables detailed study of  γγ or γγ’ biomonomer and their respective 
Fbn biopolymer formation as having different substrate behaviors of activated plasma derived 
factor XIII (pFXIIIa2b2).  High pressure size exclusion (HPSEC) and anion chromatography 
technique were used along with dynamic light scattering (DLS) and an adapted solid phase 
peptide incorporation assay. 
HPSEC analysis of the purified mixtures rFI with pFXIIIa2b2 showed greater pFXIIIa2b2 
avidity for γγ’rFI than γγrFI. This mixture could also be isolated by weak anion exchange 
chromatography. The elution profile resolved both γγ and γγ’rFI and transglutaminase activity 
showed pFXIIIa2b2 activity specifically overlapping the γγ’rFI elution peak. DLS analysis of 
pFXIIIa2b2–γγ’rFI mixture showed a high level of polydispersity index suggesting the complexes 
of different sizes.  
Kinetic studies on the effect of the γγ, γγ’rFI and rFbn in the rate of pFXIIIa2b2 activation 
were postulated to exist in three different stages. This mechanism resembles the proposed stages 
for in-vivo pFXIIIa2b2 activation.  In stage I, it was showed that γγ’ rFbn accelerates the rate of 
thrombin proteolytic removal of the pFXIIIa2b2 activation peptide. Stage II indicated that γγ’ rFI 
and γγ’-rFbn induced the faster pFXIIIa2b2 B-subunit dissociation. In the final stage, neither rFI 
nor rFbn showed an effect on the pFXIIIa2b2. This was consistent with the previously reported 
role of B chains in fibrinogen binding. 
The goal of this work focused on studying the existence and reversibility of a complex 
specifically formed between plasma derived γγ’ fibrinogen (γγ’pFI) and plasma fibronectin 
(pFN) and postulated to exist in plasma circulation.  HPSEC was used to identify and isolate the 
mixture while DLS was used to analyze the hydrodynamic size that ranged between γγ’pFI and 
pFN.  Reconstitution studies using a degraded α-chain γγ’ fibrinogen showed that the γ’ chain of 
pFI is needed to initiate complex formation. 
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CHAPTER I 
Hemostasis and Wound Healing Initiated by the Coagulation Cascade: the 
Physiology of Fibrin Formation by Fibrinogen, Factor XIII and Fibronectin. 
1.1 Overview of fibrin function at the wound site 
Injury and the physiologic response of wound stabilization and healing can be 
viewed as beginning simultaneously as the fibrin barrier acts to both seal the wound 
and as a foundation to begin healing. Fibrin is a wound adherent biopolymer of 
sufficient strength and density to stop bleeding by sealing the damaged blood vessels 
and surrounding wounded tissue. [1] It also presents structural features (such as by 
entrained platelets that are cross-linked into the polymer) that signal various cells to 
colonize it and to begin the healing process. [2, 3, 4, 5] The cessation of bleeding 
initiates a return to “steady-state” restoration of the coagulation system. The recovery 
from any systemic and local physiologic shock resulting from fluid loss (plasma and 
blood) is commensurate with “the re-establishment of hemostasis”.   
Almost instantly after injury and during the formation of the fibrin barrier to fluid 
loss, a pool of circulating inflammatory cells called neutrophils gather and occupy the 
fibrin barrier [6, 7, 8] .  This is mediated by various neutrophil integrin receptors that 
bind to ligands displayed by both fibrin and by platelets. This is a needed initiation of 
an inflammatory process which proteolytically cleans up (a debridement) damaged 
tissue that results from injury. The neutrophils participate in a simultaneous cytokine 
and growth factor signaling that emanates from damaged vascular endothelium and 
platelets entrained within the fibrin barrier at the wound site. [9, 10, 11] A 24 hour 
2 
 
time lag accompanies signals arising from this process and its conveyance to the bone 
marrow.  This results in activation, maturation and transport of macrophages from the 
bone marrow to the wound site.  Macrophages are cells with exceptional plasticity 
and the ability to differentiate into fibroblasts and endothelial cells upon colonization 
of the fibrin matrix. [12, 13]  In that context, fibrin acts as a 3-D provisional matrix 
for wound healing that is centered about staging macrophage colonization. 
   The next stage of healing then advances to the formation of a provisional tissue 
called granulation tissue.  It is formed during the next 48 hours by a network of 
fibroblasts that support a 3-D network of vasculature formed within it by endothelial 
cells both arising from differentiated macrophages. Thus, granulation tissue is 
essentially derived from fibrin colonized macrophages. [14] This network provides 
the necessary 3-D scaffold that can deliver nutrients and oxygen and simultaneously 
remove metabolites and waste products to colonizing stem cells which must build and 
restore functional tissue to the wound site. [15] A total time of about 3 to 4 days is 
needed to install well-vascularized granulation tissue during which fibrin is 
proteolytically digested. [16]  The susceptibility to proteolysis of fibrin is thus 
purposeful and at the core of the process for the rapid establishment of granulation 
tissue.  Well-vascularized granulation tissue is necessary for the next stage of healing 
which seeks to restore functional tissue from stem cells which colonize granulation 
tissue. 
1.2 Fibrin generation and the coagulation cascade 
The biochemical pathway which polymerizes fibrinogen into the fibrin matrix that 
is both a barrier to fluid loss and a 3-D provisional matrix for healing is the initiated 
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The blood coagulation cascade can be divided in two distinct and essentially 
sequentially occurring  amplification pathways: the extrinsic and the intrinsic coagulation 
pathways. [22, 23, 24, 25] In the extrinsic pathway, tissue factor (TF) is released after 
vascular injury leading to the first stabilizing pulse of fibrin called a hemostatic plug.  It 
is sometimes referred to as the TF-FVIIa pathway. The hemostatic plug is 
characteristically a first responder effort to achieve hemostasis and includes entrained 
platelets which immediately catalyze both thrombin generation and cell signaling that 
gathers circulating neutrophils.  After this initial fibrin generation, the same thrombin 
triggers the intrinsic pathway resulting in a >1500-fold kinetic surge of additional 
thrombin.  It is this thrombin that generates the bulk of fibrin needed to ultimately finish 
the hemostatic and “provisional matrix for healing” roles of the fibrin barrier. [25] It is 
noted that thrombin acts penultimately in multiply nested enzyme reaction steps to assure 
insoluble fibrin formation including activation steps of fibrinogen to fibrin monomer and 
also of intrafibrin and wound ECM crosslinking.   
The extrinsic pathway is centered about the initial exposure of TF caused by 
wounding. [23] It is a cell bound transmembrane glycoprotein and class II cytokine, 
operates as both a signal transduction and a factor VII cofactor. As a signal transduction, 
TF  induces the genes involved in inflammation, embryonic development and cell 
migration and as cofactor TF  binds and activates coagulation factor VII (FVII) in a 
process named blood coagulation initiation. The newly formed complex proteolytically 
activates the coagulation factor IX (FIX) and factor X (FX) into FIXa and FXa. The 
association of FXa with the cofactor Factor V activates small amounts of prothrombin to 
thrombin. [22]  
5 
 
Large amounts of FXa (>1500-fold kinetically higher amounts is generated than is by 
VIIa pathway) are generated by the formation of tenase complex involving FIXa and 
FVIIIa. [17, 22] The activation of FVIIIa and FIXa is catalyzed by small amounts of 
thrombin formed from the FVIIa activation pathway. This results in large amounts of 
prothrombinase complex to generate a very large surge of thrombin necessary to seal the 
wound in a lasting manner.  It is noteworthy that the FIXa-FVIIIa-FXa tenase complex 
formation is precluded in individuals with hemophilia A and hemophilia B. [17] The 
formation of FXa forms a complex with FVa on the platelet surface receptors forming 
prothrombinase complex that converts prothrombin to thrombin. As final steps, thrombin 
activates fibrinogen and factor XIII to induce fibrin polymerization and the formation a 
stable fibrin matrix. [24, 25] Thus, thrombin activity is self amplifying.  It is feedback 
controlled by inhibitors such as antithrombin III and the inactivation of Factor Va and 
Factor VIIIa caused by activated protein C.  Protein C is activated by thrombin. 
The polymerization of fibrinogen, figure 1.2, begins with the thrombin proteolytic 
cleavage of the fibrinopeptide A (fpA) contained on the fibrinogen (FI) Aα chain and the 
fibrinopeptide B (fpB) located in the Bβ chain. The release of the fpA and fpB generates 
the exposure of independent polymerization sites EA and EB which combines respectively 
with a constitutive complementary DA and DB pocket located in the D domain of adjacent 
FI molecules. [26, 27, 28, 29] The release of the fpA expose the Gly-Pro-Arg (GPR) 
motif which associates with DA pocket resulting in the formation of a strong and stable 
double-stranded fibril which in turn undergo lateral association to form a complex fibrin 
network. In the other hand, the release of the fpB exposes the Gly-His-Arg-Pro (GHPR) 
motif allowing the interactions with the DB pocket. This later interaction is not 
6 
 
completely required for lateral fibril association but it contributes to this process through 
cooperative interactions. The further assembly of fibrin begins with the formation of 
double stranded fibrils. Interactions of fibrin monomers occurs in a half staggered manner 
inducing the formation of large fibrin oligomers which lengthen further to make 
protofibrils. Protofibrils lateral aggregation leads to the formation thicker or thinners 
packed fibers which is catalyzed by the enzymatic activity of factor XIII. [30, 31] Further 
fiber branching occurs by bilateral and equilateral junction. The first occurs when a 
double –stranded fibril converges laterally with another fibril to form a four-stranded 
fibril. The equilateral junction occurs when three fibrin molecules converge they form a 
three double stranded fibril. Finally, these associations give rise to the formation of a 3-D 
network which in turn induce the formation of a fibrin clot and consequently the initial 
structure for the incorporation of different proteins including fibronectin, Von Willebrand 
factor (a circulating protein with platelet and ECM-collagen wound adherence, that is a 
large macromolecule with potential for polymeric structures >1M kDa) , vascular 
endothelial growth factor that contributes to tissue repair. [32, 33]  
1.3 The process for fibrin entrainment of Fibronectin needed for cell colonization 
signaling  
One form of Fibronectin (FN) is a large 440 kDa glycoprotein is produced and 
secreted by hepatocytes into blood plasma where circulates at 300–400 µg/mL.  Other 
forms of FN are designated as “cellular fibronectin (cFN): and are produced by most cells 
for integration into their ECMs.  For example, macrophages, fibroblasts and epithelial 
cells all produce cFN.  pFN and cFN are can be distinguished by their differences in 
structure that impart solubility: plasma FN is soluble enabling it to circulate while cFN 
 h
3
w
fp
ag
fi
as limited so
5, 36]  Ho
oundsite by
 
Figure 1.
A and fpB
gregation w
nal step of t
 
lubility lead
wever, pFN
 the crosslin
2.: Fibrin p
.  Knob-hol
hich induce
he fibrin ma
ing to its im
 can be in
king provid
olymerizatio
e interaction
s further pa
trix formatio
mediate EC
corporated 
ed transgluta
n initiates 
s between 
cking and br
n. 
M incorpor
into the fib
minase fact
by the prot
D domains 
anching. Bi
ation upon 
rin matrix 
or XIII (FX
eolytic throm
and E dom
lateral junct
its secretion
evolving a
III).   
bin remov
ains start la
ion occurs a
7 
. [34, 
t the 
 
al of 
teral 
s the 
8 
 
Several important structural characteristics result from the installation of pFN into the 
fibrin matrix.   pFN provides stability and viscoelastic strength to the nascent fibrin 
matrix. [32]  In addition, the altered pFN conformation resulting from crosslinking into 
fibrin matrix exposes signaling residues for integrin receptors. These exposed ligands are 
key to triggering of  angiogenesis.  For example, cross-linked pFN induces the integrin 
expression of α4β1, α5β1 in quiescent endothelial cells and subsequently αvβ3, αvβ5 
during angiogenesis. [37, 37]  
The migration and proliferation of endothelial cells within the fibrin matrix during the 
early stages of wound healing and angiogenesis is dependent on the presence of cross-
linked pFN.  [37] pFN is also well known for its significance in physiological process 
such as cell adhesion, migration and wound healing. Once fibronectin is crosslinked into 
the fibrin matrix by the action of the transglutaminase factor XIII (FXIII), fibronectin 
RGD (Arg-Gly-Asp) peptide residues serves as a signal for the binding of transmembrane 
integrin proteins in endothelial cells. [26, 38, 39] Thus, the engineering of the 
incorporation of pFN into the fibrin matrix by FXIII can be used as method to regulate 
cellular association, migration and proliferation. 
1.4 FXIII activity and the engineering of the incorporation of pFN into the fibrin 
matrix.   
The in vitro and in situ engineering of strong fibrin matrices including those 
incorporating pFN  such as occurs in fibrin based surgical sealants requires FXIII 
activity.  In that context, the cross-linking by FXIII has a multi-faceted impact on fibrin 
stability.  For example, the cross-linking of fibrin by FXIII renders resistance of the fibrin 
9 
 
to fibrinolysis.  In vivo, a balance of resistance to fibrinolysis and fibrin stability is 
essential for the development of fibrin clot strength while mitigating the danger of emboli 
formation.  The catalytic activity of FXIII on the fibrin cross-linking also regulates the 
plasminogen binding to the fibrin network.  This fibrinolytic process is regulated by 
covalent binding presence of α2 antiplasmin to fibrin. FXIII also regulates the platelet 
attachment to fibrin matrix by crosslinking the γ-chains which in turn alters the platelet 
binding site inducing the down regulation of platelet adhesion to the fibrin matrix. [40] 
[41, 42] As mentioned above, the covalent attachment of FN to the fibrin matrix during 
this process influences the clot elastic properties and the fiber size and density. [43, 44] 
The physiologic impact of fibrin sealants used at wound sites will undoubtedly be 
complex and have wound healing properties impacted by FXIII activity and the 
fibrin:pFN polymer structure it catalyzes.  Briefly, these can be anticipated by 
physiologic abnormalities associated with FXIII deficiencies. For example, FXIII has 
been demonstrated to be important to embryonic fibroblast growth.  FXIII deficiencies 
affect the normal fibroblast growth producing cells of irregular shape which consequently 
affect the ECM associated collagen production associated with tissue development. [45]   
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CHAPTER II 
Biophysical properties of Fibrinogen, Factor XIII and Fibronectin: molecular 
structure and interactions 
2.1 Fibrinogen (FI) structure 
Fibrinogen a 340 kDa human plasma glycoprotein that is comprised of two sets of 
disulfide-bridged Aα chain (66.5kDa), Bβ chain (52kDa), and γ chain (46.5). Each FI 
molecule symmetrically presents two D domains connected to a central E hub domain. [1, 
2] FI is formed by 6 chains held together by disulfide bonds in the E region. These chains 
extend from the E region forming two symmetric half molecules. The D region is mainly 
conformed by the C-termini of the Bβ and γ which form a globular domain. At 
physiological conditions FI behaves as a straight rod shape molecule with a 
hydrodynamic radius (RH) of 10 ± 0.1 nm as measured by dynamic light scattering (DLS) 
[3, 4].  FI presents two variants of γ chains arising from differential mRNA splicing 
leading to the substitution of 4 carboxy terminal amino acid residues of the γ chain by a 
more acidic 20 amino acid sequence. (Figure 2.1)  [5, 6, 7] . The presence of this 
sequence leads to an approximate 90% occurrence of FI in normal human plasma 
containing a “homodimeric” γγ content with 10 % of FI containing “heterodimeric” γγ’.  
This variation introduces different biochemical characteristics that are mainly related to 
its interaction with plasma factor XIII, fibronectin and also fiber thickness, protofibril 
packing, intrafibrillar structure and clotting strength [8, 9, 10] 
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thicker fibers. These structures are rendered insoluble by the enzymatic cross-linking 
activity of factor XIII.  Fiber branching occurs when a double-stranded fibril converges 
laterally aligns with another fibril to form a four-stranded fibril. A “three double stranded 
fibril” occurs when three fibrin molecules converge they form a fibril. Finally, these 
associations and cross-linking give rise to the formation of an insoluble 3 dimensional 
network that is a core part of the fibrin barrier and provisional matrix. [11, 12, 14, 15, 
16].  However, the specific pathways for pFN integration have not been detailed and are a 
function of FXIII activity. Structural differences in fibrin polymer occur when 
polymerized from γγ versus γγ’ F1.  For example, fibrin polymer made in vitro with γγ’ 
exhibits smaller pores when visualized by Transmission Electron Microscopy (TEM). 
[17, 8, 18, 10]  
2.2 Factor XIII (FXIII) structure 
Plasma factor XIII (pFXIIIA2B2) is composed of two A catalytic sub-unit and two B 
carrier subunits (Figure 2.2). [19] Factor XIII also occurs on the surface of platelets as a 
dimer of two A catalytic sub-units. This dimeric form is also named cellular factor XIII 
(cFXIIIA2). Both pFXIIIA2B2 and cFXIIIA2 of platelets are transformed to the same 
activated dimers by thrombin proteolysis in the presence of physiological levels of 
calcium which induces to structural modifications. About 50% of the resulting factor XIII 
crosslinking activity is supplied to the polymerization reaction of fibrin by pFXIIIA2B2. 
This cross-linking is catalyzed by transglutaminase activity which forms covalent bonds 
between γ-γ, γ-α and α-α of adjacent fibrin molecules stabilizing the protofibrils. [20, 21, 
22]  
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2.4.1 Fibrinogen and factor XIII (pFXIIIA2B2) 
It was initially stated that plasma factor XIII binds fibrinogen trough the factor 
XIII-A subunit suggesting that pFXIIIA2B2 circulates in plasma bound to fibrinogen. [38] 
Later studies focused on the identification of the fibrinogen binding site for pFXIIIA2B2, 
indicated that the fibrinogen γ’ peptide chain is responsible for the interaction with 
pFXIIIA2B2 via the B subunit. [39] However, studies using surface plasmon resonance 
(SPR) identified a pFXIIIA2B2 binding region located in the αC region of fibrinogen. [40] 
Further investigation in the plasma Fibrinogen–Factor XIII interactions, showed that the 
fibrinogen γ chain residues 390-396 provides binding sites for pFXIIIA2B2 via the B 
subunit [41]. Based on these findings, it was suggested that the stoichiometric ratio of 
pFXIIIA2B2-fibrinogen interaction is 1:1 [41] However, due to the tetrameric nature of 
the factor XIII ( 2 subunit-B and 2 sub-unit A) it was also suggested that the interaction 
pFXIIIA2B2-fibrinogen occurs in a 2:1 ratio via the factor XIII subunit-B [42]. All these 
results presented above showed convincing evidence of the intrinsic nature of the 
interaction between the soluble FI with pFXIIIA2B2. However, some characteristics of 
these interactions are not quite completely explained. First, it is not quite clear what 
biophysical changes emerge from the interaction between the two main variants of 
fibrinogen: the homodimer γγ and the heterodimer γγ’. Second, it was stated that 
preparations of factor XIII free fibrinogen are quite complicated to obtain and it is only 
achievable by thermal denaturing of FI. Thus, all the previous experiments conducted 
using plasma fibrinogen may have misleading results as pFXIIIA2B2 may be present as 
an impurity. The previous statement is important during the activation assays as some 
23 
 
pFXIIIA2B2 content may affect the real contribution of the fibrinogen variants on the 
pFXIIIA2B2 activation mechanism. 
2.4.2 Fibrin and factor XIII 
While the interaction between fibrinogen and pFXIIIA2B2 has been extensively 
studied, the specific binding phenomenon is complicated by the heterologous nature of 
the cross-linking of fibrin by activated FXIIIA2*. This is related to the fibrin matrix 
changes as it becomes insoluble due to the cross-linking process (figure 2.5 Insoluble 
phase). Specifically, pFXIIIA2B2-fibrin interactions were studied on the basis of the 
pFXIIIA2B2 activation mechanism. As presented in figure 2.3, the complete exposure of 
the pFXIIIA2* catalytic triad occurs only in the presence of fibrin which reduces the 
concentration of calcium required for both the B-subunit dissociation and the structural 
modification to expose the catalytic core in the enzymatic pFXIII A subunit. [43, 44]. 
The nature of this interaction was also investigated by the formation of a termolecular 
complex between Fibrin–Thrombin–pFXIIIA2B2 which enhances the rate of proteolitic 
removal of the activation peptide within the pFXIIIA2B2. [45] However the major 
interaction between Fibrin–pFXIIIA2* occurs during the fibrin crosslinking as fibrin acts 
as both cofactor and substrate during the crosslinking process. As a substrate, fibrin 
provides amino acid residues glutamine and lysine which are involved on the crosslinking 
phenomena. In short, the cysteine residue in the active pFXIIIA2* acts as nucleophile 
attacking the side chain of the glutamine (Q) residues on fibrin. Then, after the release of 
the ammonia from glutamine the acyl glutamil residue bond to the factor XIII catalytic 
triad, binds the primary amine from a lysine (K) residue forming the isopeptide bond. 
Crosslinking occurs more rapidly on the γ-chains between the γQ398 and or γQ399 and 
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γK406 [46]. Then, crosslinking of the α-chains occurs between αQ221, αQ237, αQ328, 
αQ366, and various Lysine residues. In the other hand, fibrin acts as cofactor by (a) 
reducing the amount of calcium required to separate A and B factor XIII subunits, (b) 
inducing the factor XIII B subunit dissociation from the previously thrombin 
pFXIIIA2B2, (c) triggering conformational changes on the pFXIIIA2’ to form the fully 
active pFXIIIA2* (Figure 2.3). Thus, the predominant effect of fibrinogen on the 
activation of the pFXIIIA2B2 is as a cofactor. However, due to the fact the plasma 
fibrinogen preparations contain traces of pFXIIIA2B2 the actual evaluation of the FI 
effect on the rate of pFXIIIA2B2 activation may incur in unexpected deviations.  
2.5 Interactions between Fibrinogen and fibronectin 
As in the pFXIIIA2B2–FI interactions, the analysis of the plasma fibronectin–
fibrinogen (pFN-FI) interactions were studied based in the pFN ability to bind fibrinogen 
and/or fibrin. Previous work suggested that the cold insoluble globulin (CIg), later 
renamed as fibronectin, induce the cryoprecipitation of fractions containing fibrin-
fibrinogen complexes but not fibrinogen alone suggesting the pFN greater avidity toward 
fibrin molecules.[52] Further studies showed that the fibrinogen conversion to fibrin was 
necessary for the interaction of the fibrin αC chain and fibronectin [53]. However, the 
identification of a soluble 1:1 ratio FI–FN complexed molecule was detected by 
hydrodynamic light scattering studies of plasma collected from patients with rheumatoid 
arthritis suggesting that the intrinsic interaction of fibrinogen and fibronectin was 
facilitated by the FN structural flexibility in free motion. [48] In our recent work, we 
observed the formation of a γγ’FI-FN complex molecule in human plasma cryoprecipated 
25 
 
and isolated by DEAE at room temperature. Moreover, the thromboelastographic analysis 
showed that the γγ’FI-FN complex increases the clotting strength when compare with 
γγ’FI and γγ’FI at the same concentration. Our findings were also extended to the 
crosslinking characterization of the γγ’FI-FN mixture which present a periodical pFN 
crosslink into fibrin fibers a phenomenon that was not observed with the γγFI-FN 
mixture. [9] These finding lead us to perform a deep biophysical evaluation of 
interactions between pFN and the two major variants of FI: (a) the homodimer γγ and (b) 
the heterodimer γγ’ and have a complete understanding on the nature of the FN and γγFI-
FN, γγ’FI interactions. 
2.6 Dissertation Objectives  
In an effort to reconcile previous studies and present new evidence of interaction between 
fibrinogen and pFXIIIa2b2 and the effect of fibrinogen on the activation mechanism of 
pFXIIIa2b2 the present work have the following specific objectives.  
1. Provide evidence of the role of the fibrinogen γ’ chain on the interaction with the 
plasma derived factor XIII by analytical methods including high pressure size 
exclusion and dynamic light scattering.  
2. Identify the stage at which the γγ and γγ’ variants of fibrinogen exert the co-factor 
effect in the pFXIIIa2b2 activation mechanism.  
This work is also extended to the characterization of the non-covalent binding between 
fibrinogen and fibronectin. Thus, the additional objectives are included in this 
dissertation. 
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3. Characterize the interaction of plasma fibrinogen and plasma fibronectin by analytical 
methods including dynamic light scattering. 
4. Evaluate the effect of fibrin on the formation of a stable fibrinogen-fibronectin 
mixture. 
5. Assess the influence of the fibrinogen γ’ and α chain and their interactions with 
fibronectin. 
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CHAPTER III 
Interactions with γγ and γγ’ Recombinant Fibrinogen: Tetrameric Plasma factor 
XIII and Recombinant Monomeric Factor XIII Binding 
3.1.Summary and Background. 
Past reports describing the binding of tetrameric plasma derived plasma factor XIII 
(pFXIIIA2B2) to γγ’pF1 used the coincidentally eluting anion chromatographic fractions 
of these two proteins as evidence of the complexation. [1]  pFXIIIA2B2  normally occurs 
in plasma at about only 3-4 ug/ml (about 0.07 um) while  γγ’pF1 occurs in plasma 
circulation at only 300 ug/ml (at about 9 uM).  These studies estimated that pFXIIIA2B2 
binds about 1 out every 100 γγ’rF1 and thus the ratio of cross-linking enzyme to fibrin 
substrate is typical of enzyme catalyzed reaction masses. [2, 3]  The complexation with 
γγ’pF1 serves to target the delivery of FXIII zymogen to the wound where fibrin polymer 
must be cross-linked by activated FXIII that decomplexes from the γγ’pF1 after thrombin 
activation. [4, 5, 6]   
The future medical uses of this unique and abundant source of recombinant human 
fibrinogen and the recombinant FXIII made by Pichia Pastoris would logically benefit 
from a full characterization of their behavior together relative to that of pF1 and 
pFXIIIA2B2. The post-translational character of the γγ’rF1 contains less sulfation of the 
tyrosines contained in the carboxy terminal end of the γ’ chain. [7] The monomeric 
recombinant A subunit factor XIII (rFXIIIA1) studied here has a contrasting absence of 
the B domain subunits to that occurring in pFXIII.  In this chapter we characterize the 
33 
 
binding of pFXIIIA2B2 and also monomeric recombinant Factor XIII (γγ’rF1) to γγpF1 
and γγ’pF1 and also γγrF1 and γγ’rF. We use a combination of anion exchange and 
HPSEC chromatographic fractionation techniques along with dynamic light scattering 
(DLS) of the fractionated samples.  In contrast to the 10:1 presence of γγpF1 and γγ’pF1 
in plasma, we also evaluated γγrF1 and γγ’rF1 which are both expressed at about 2 g/l in 
the milk of transgenic cows.  We have also made rFXIIIA1 in Pichia and find it a useful 
component in the recombinant fibrin surgical sealant formulations we have studied.    
HPSEC was shown to resolve pXIIIA2B2 from γγ’pF1 and also from γγ’rF1 as 
well as pXIIIA2B2 from γγpF1 and also from γγrF1.  The binding of pXIIIA2B2 to γγ’pF1 
was indicated by a single peak eluted from a mixture made of pFXIIIA2B2 and γγ’pF1.  
This contrasted separate peaks eluting from a mixture made of pXIIIA2B2 and γγpF1 that 
showed no significant binding behavior. The presence of functional pFXIIIA2B2 
zymogen was tracked by transglutaminase activity assay that we have adapted from past 
reported studies. Transglutaminase activity  assessment of the above chromatography 
product eluates showed that the majority of pFXIIIA2B2 activity did not form an 
association with the γγpF1.  However, the mixture made of pFXIIIA2B2 and γγ’pF1 
showed transglutaminase activity superimposed with the single peak containing γγ’pF1 
that was eluted by HPSEC processing of that mixture.   
A similar behavior was observed when mixing pFXIIIA2B2 with γγ’rF1. Of 
particular significance was that γγ’rF1 and γγrF1 which are both recombinantly produced 
and therefore contain no pFXIIIA2B2.  Thus, a mixture of pFXIIIA2B2 together with 
γγ’rF1 and γγrF1 enabled the study of pFXIIIA2B2 avidity for γγ’rF1 that was without 
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background pFXIIIA2B2 activity.  For example, the study of an association of 
transglutaminase activity specifically with γγ’rF1 was done when a mixture of 
pFXIIIA2B2 together with γγ’rF1 and γγrF1 was followed by the resolution of the γγ’rF1 
by processing the mixture by DEAE chromatography.  The DEAE chromatography 
resolved γγ’rF1 from γγ’rF1 where the activity assay indicated that the majority of the 
pFXIIIA2B2 that was added to the mixture co-eluted as a coincidental peak along with the 
γγ’rF1. The role of B domain in γ’ chain binding of the heterodimeric γγ’pF1 as reported 
in previous studies was also investigated using rFXIIIA1.  In contrast to γγ’pF1 studies 
using pFXIIIA2B2, neither γγrF1 or γγ’rF1 were observed to associate with rFXIIIA1 
when evaluated by HPSEC.  Thus, the absence of the B domain in rFXIIIA1 is consistent 
with the lack of binding with γγ’rF1 by rFXIIIA1 as observed in our HPSEC studies.  
3.2.Introduction  
Plasma factor XIII (pFXIIIA2B2) is a member of the transglutaminase enzyme 
family that circulates in plasma as a hetero-tetrameric protein conformed of 2A and 2B 
sub-units which act as the enzymatic and carrier peptide respectively. [8, 9, 4, 10] The A 
subunit is a single polypeptide chain consisting of 731 amino acids with a molecular mass 
of 83kDa and it is composed of two β barrels, a β sandwich, the catalytic core peptide and 
the activation peptide residue at the N-terminal that is removed upon thrombin activation. 
[11, 2, 6, 12] The B subunit consists of 641 amino acids organized in 10 tandem repeats 
termed sushi domains which prolong the lifespan of the catalytic subunit. [13, 14, 10] 
The activation of pFXIIIA2B2 occurs in two sequential steps. First, thrombin cleaves an 
activation peptide from the N-terminal in the A subunit. Then, the dimeric dissociation 
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from the B subunit takes place on the presence of calcium giving rise to the dimeric 
structure of activated factor XIII (pFXIIIA2*) which stabilize the nascent fibrin matrix in 
the early stages of blood clot formation. [15, 16, 17, 18] 
The interaction between fibrinogen and pFXIIIA2B2 has been largely studied.  [3, 
19, 1, 20, 21, 22, 4] Greenberg and Shuman showed specific pFXIIIA2B2 binding to 
fibrinogen by the A2 subunit suggesting that pFXIIIA2B2 circulates in plasma bound to 
fibrinogen. Hornyak and Shafer studied the non-active pFXIIIA2B2 and platelet FXIIIA2 
binding to fibrin. [19] They indicated that the binding of platelet FXIIIA2 was weaker 
than the zymogen pFXIIIA2B2. Additional studies focused on the identification of the 
fibrinogen binding site for pFXIIIA2B2, indicated that the fibrinogen γ’ peptide chain is 
responsible for the interaction with pFXIIIA2B2 via the B subunit. [1]Smith et al. used 
surface plasmon resonance to show that the pFXIIIA2B2 binds to the αC region of 
fibrinogen [20]. In a recent study, Byrnes et al. identified the fibrinogen γ chain residues 
390-396 as the primary binding residues for pFXIIIA2B2 via the B subunit. Based on 
these findings, Byrnes suggested that the interaction of pFXIIIA2B2-fibrinogen occurs in 
a 1:1 stoichiometric which differs from the 1:2 pFXIIIA2B2:fibrinogen proposed by 
Moadel. [21] In either case, binding of pFXIIIA2B2 to the α, γ or γ’ chains generates 
physical and conformational changes on the fibrinogen structure.  
Physical studies characterized fibrinogen as a straight rod shaped molecule with an 
over-all length of 47.5±2.5 nmand a hydrodynamic radius (RH) ranging from 10nm to 
18nm determined by dynamic light scattering (DLS) under physiological conditions. [23, 
24, 25] Huang and Lord identified fibrinogen species of high molecular weight with a RH 
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from 11nm to 200nm. [26] However the isolation of fibrinogen monomers via size 
exclusion chromatography showed a RH of 10±0.1nm which is consistent with previous 
findings. Further studies on the fibrinogen polymerization showed large fluctuations on 
the fibrinogen diffusion constant due to conformational changes after enzymatic 
activation [27, 28, 6] which can be interpreted as the increase of the RH. Same results 
were observed by Ping et al. during the polymerization of fibrinogen monomers. A rapid 
increase on the RH was detected after the enzymatic thrombin activation. [29] Here, we 
assess the conformational changes arising from the interaction between the non-activated 
zymogen pFXIIIA2B2 and the two major variants of a recombinant fibrinogen (rF1), γγ 
and γγ’, produced in milk of transgenic cows. [30] Furthermore, we used high 
performance size exclusion chromatography (HPSEC) to isolate complexed molecules 
formed by either pFXIIIA2B2:γγrF1 or pFXIIIA2B2:γγ’rF1. A second pass of the 
concentrated fractions was performed in order to confirm the existence of a single 
complexed molecule. Our HPSEC results confirmed the high affinity of the pFXIIIA2B2 
towards γγ’rF1. Meanwhile, An increased on the RH and the polydispersity percentage 
suggests the formation of complexed molecules when pFXIIIA2B2:γγ’rF1 is evaluated by 
DLS. These findings contribute to resolve the apparent contradictions in the role of the γ’ 
chain in the interaction with the pFXIIIA2B2 and provide new insights into the complex 
pFXIIIA2B2:γγ’rF1 conformational rearrangements. 
3.3. Materials and Methods 
3.3.1. Materials. All reagents were purchased form Fisher-Scientific unless otherwise 
stated. Recombinant activated thrombin (20000 units) was purchased from 
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Zymogenetics (WA). 1000U/mL aliquots were prepared in 0.9% NaCl and stored 
at -80 ⁰C until use. Human plasma factor XIII, (pFXIIIA2B2) containing a specific 
crosslink activity of 2650 Loewy units/mg was purchased from Enzyme Research 
Laboratories (IN). FPR-chloromethylketone (PPACK) was purchased form 
Haematologic Technologies Inc. VT.  
3.3.2. Recombinant factor XIII. Monomeric recombinant factor XIII (rFXIIIA) was 
intracellular expressed in the yeast Pichia pastoris X-33 as previously described 
[31]. rFXIIIA was purified in a His-Bind® nickel charged resin column. rFXIII 
specific activity was estimated to be 153 PEU/mg using a peptide incorporation 
assay. 
3.3.3. Recombinant fibrinogen.(rF1). The human recombinant fibrinogen was 
expressed in the milk of transgenic dairy cows and purified by a two-column 
purification procedure using cation exchange (CIEX) and hydrophobic interaction 
chromatography (HIC). [7, 1]  
3.3.4. Anion Exchange Chromatography. Purified rF1 was loaded to the weak anion 
exchange DEAE Sepharose™ Fast Flow column to isolate γγ and γγ’ species by 
pH gradient as previously described. [1] After γγ and γγ’ were isolated, 1:9 molar 
ratio γγ’: γγ rF1 were mixed with pFXIII to a final molar ratio 1:10 pFXIII: total 
rF1. The mixture was loaded onto a DEAE sepharose equilibrated with 50nm 
Sodium Citrate, 150mM NaCl, pH7.4. Gradient elution was performed increasing 
salt concentration. Collected fractions were pooled and concentrated down to 
determine the pFXIII activity using peptide incorporation assay.  
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3.3.5.  High Pressure Size Exclusion Chromatography (HPSEC). Mixtures of factor 
XIII and fibrinogen (γγ or γγ’) were prepared in 50mM Tris buffer, 115 mM 
NaCl, pH 7.5 maintaining ionic strength of 0.15. The mixtures were incubated 
for 1 hour at 37°C and 200μg of the mixture were loaded into two superose 6 
10/300 (GE lifescience) columns connected in series to a Knauer (Berlin, 
Germany) Smartline chromatography station. The columns were isocratically 
eluted using Tris Buffer at a flow rate of 0.35 mL/min and the length of the run 
was 90 minutes for all the samples. Effluent’s absorbance was read at 280nm and 
collected fractions were assayed for Factor XIII activity, SDS-Page,  and particle 
size distribution using a Dynamic Light Scattering instrument. 
3.3.6. SDS PAGE gel electrophoresis. Non-reduced and reduced samples of pFXIII, γγ 
and γγ’rF and their mixtures were evaluated by sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% NuPage Bis-Tris pre-
cast gels (Thermofisher, CA). All the gels ran for 1 hour at 200 volts and then 
stained with colloidal Blue gel stain (Invitrogen, CA, USA).  
3.3.7. Factor XIII Biotinamino-pentylamine incorporation activity assay. The factor 
XIII mediated incorporation of Biotinamino-pentylamine to γγ or γγ’ rF1 was 
determined using the 5 Biotionamido-pentylamine assay. [20] In brief, 100 μL of 
40μg/mL of γγ or γγ’rF1 were poured into each well of a 96 high binding 
microtiter plate. Then plates were incubated for 1 hour at 37°C. Blocking buffer 
(1%BSA in TBS) was added to the wells and incubated overnight at room 
temperature. The adsorbed fibrinogen was converted to fibrin monomers by 
adding 100μL of 1.11 NIH U/mL rFIIa. Then, 50μL of crosslink substrate mix 
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(0.25mM 5bapa, 0.1mM DTT and 1.1 mM CaCl2) was added to each well and 
incubated for 10 minutes at room temperature. Thereafter, 50μL of activated 
pFXIIIA2* or rFXIIIA* was added to each well and the plate was incubated for 30 
minutes at room temperature. 200μL of 200mM EDTA were added to each well 
to quench transglutaminase reaction. 100μL of 2.0 μg/mL Streptavidin alkaline 
phosphatase solution was added to each well and incubated at 37⁰C for 1 hour. 
After incubation, plates were washed and 100μL of para-nitrophenyl phosphate 
(p-NPP) dissolved in 1M Diethanoalamine was added to the wells. The color 
developing (clear to yellow) indicated the phosphatase activity on the p-NPP 
substrate. Finally, the reaction was stopped by adding 200μL of 4N NaOH after 2 
minutes reaction. The plates were read at 405nm using Beckman Coulter AD340 
plate reader. The results were expressed in units of optical density. 
3.3.8.  Dynamic Light Scattering. The hydrodynamic radius (Rh) and particle size 
distribution were estimated by dynamic light scattering using the DynaPro99 
Titan Instrument (Wyatt Technology, CA). In Brief, 20μL of samples containing 
either rγγF1 or rγγ’F1 or in mixture with pFXIII were illuminated by a 830nm 
laser and the intensity of light scattered was measured by an avalanche 
photodiode. The fluctuations in the measured intensity specify the diffusion 
coefficient which is estimated by autocorrelation analysis. Finally, the particle 
hydrodynamic radius is determined by using the Stroke-Einsten relationship 
which assumes the uniform sphere shape of the analyzed particle. Isolated 
samples of rγγF1, rγγ’F1, pFXIII and their combinations were prepared and 
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analyzed at different concentrations ranging from 0.5 to 2.5 mg/mL. The buffer 
ionic strength was controlled by adding NaCl from 0.15. 
3.4. Results 
3.4.1. γγ/γγ’rF1 isolation. Purified rF1 was loaded into DEAE fast flow sepharose 
column and eluted by linear salt gradient. [1] Two peaks were observed in the 
chromatogram and further SDS-PAGE peak analysis indicates that the first and 
the second peak correspond to the γγrF1 and γγ’rF1species respectively. Figure 
2.1 shows the chromatogram profile for the γγ and γγ’ rF1 isolation. 
  
Figure 3.1: DEAE-Sepharose chromatography of γγ and γγ’ rF1 isolation. 
3.4.2.  HPSEC pFXIII- γγ/γγ’rF1 interaction. In order to understand the interactions 
of pFXIII and fibrinogen species γγ and γγ’, free factor XIII recombinant γγ and 
γγ’ fibrinogen were mixed with pFXIII and evaluated by high pressure size 
exclusion chromatography. Figure 2.1 shows the HPSEC γγ rF1 and pFXIII 
chromatograms profile. In these experiments, γγ rF1 and pFXIII eluted as a 
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single peak at minute 61.2 and 68.9 respectively (figure 2.1 panel A). When 
pFXIII and γγ rF1 were mixed in a 1:10 molar ratio, two peaks were eluted as 
presented in panel B. The eluate was collected in 3 fractions (1,2,3) and analyzed 
by non-reduced SDS-PAGE (panel C). It is observed that fraction 1 which 
corresponds to the first peak is mainly composed of γγ rF1 without any 
observable pFXIII. However, some pFXIII can be observed in Fraction 2 which 
corresponds to the intersection of peak 1 and peak 2. Fraction 3 is composed 
mostly of pFXIII and corresponds to the second peak in the chromatogram (panel 
B). To evaluate if the collected fractions correspond to a single complexed 
molecule, fractions 1, 2 and 3 were reloaded to the HPSEC and evaluated it as 
indicated in the methods section. The chromatogram profiles along with their 
corresponding SDS-PAGE gels are presented in panels D to I. In panel D, 
fraction 1 eluted as a sharped peak followed by a long tail which may indicate 
the presence of some of small quantity of complexed γγrF1:pFXII molecules. 
However, No visible pdFXIII is observed in the SDS-PAGE gel (panel E). Panel 
F represents the chromatogram profile for fraction 2. Two consecutive peaks 
centered at minute 61 and minute 68 were observed in the chromatogram. The 
SDS-PAGE demonstrates that the main peak is mainly composed of γγ rF1 
meanwhile pFXIII is the main component of the small peak centered at minute 
68. This result proves that fraction 2 in panel C is not composed of a single 
complexed molecule but represents the intersection of γγ rF1 tail and the front 
head of pFXIII. Finally, fraction 3 which corresponds to the second peak in panel 
B was reloaded into the HPSEC system. Panel H represents the elution profile of 
42 
 
fraction 3 and panel I its corresponding SDS PAGE. The chromatogram shows 
the formation of a single peak which is mainly composed of pFXIII with no 
observable γγ rF1 as indicated by the SDS-PAGE.  
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Figure 3.2: High Pressure Size Exclusion, Panel A: γγ rF1 (solid line), pFXIII (dashed 
line), Panel B: γγ rF1 with pFXIII (10:1 mass ratio). Panel C: Non-reduced SDS-PAGE 
γγ rF1-pFXIII mixture. Lane 1: γγ rF1, Lane 2: Fraction 1, Lane 3: Fraction 2, Lane 4: 
Fraction 3, Lane 5: pFXIII. Panel D: HPSEC fraction 1 Panel E: Non-reduced SDS-
PAGE fraction 1 γγ rF1-pFXIII mixture. Lane 1: fraction 1a, Lane 2: fraction 1b, Lane 3: 
fraction 1c, Panel F: HPSEC fraction 2 Panel G: Non-reduced SDS-PAGE fraction 2 γγ 
rF1-pFXIII mixture. Lane 1: fraction 2a, Lane 2: fraction 2b, Lane 3: fraction 2c,  Panel 
H: HPSEC fraction 3 Panel I: Non-reduced SDS-PAGE fraction 3 γγ rF1-pFXIII 
mixture. Lane 1: fraction 3a, Lane 2: fraction 3b, Lane 3: fraction 3c.   
 When γγ’rF1 and pFXIII were mixed and loaded into a HPSEC system, a peak 
centered at minute 60.74 and shoulder protruding at minute 65 can be observed in the 
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chromatogram profile  presented in figure 2.2 panel B. The displacement in the normal 
elution of pFXIII showed in panel A may indicate an intrinsic interaction between γγ’rF1 
and pFXIII. To prove this reasoning, the eluted fractions 1,2 and 3 were collected and 
analyzed in a non-denatured SDS-PAGE. From the gel presented in panel C, It can be 
observed that all the fractions contained pFXIII. To identified if those fraction form a 
single complexed molecule, all the fractions were reloaded to the HPSEC system. 
Fraction 1 elutes as a single peak centered at minute 60.7 which prove the existence of a 
single complexed molecule. The analyzed fractions, 1a, 1b and 1c, indicates the 
interaction of γγ’rF1 and pFXIII. When fraction 2 was reloaded to the HPSEC system, a 
main peak centered at minute 60.8 and a shoulder protruding around minute 65 was 
observed in the chromatogram profile (panel F). The collected fractions were analyzed by 
SDS-PAGE and presented in panel G. It is observed that pFXIII is presented in all 
fractions (b1,b2 and b3). We can state that the observed shoulder in the chromatogram 
profile may indicated the saturation of γγ’rF1 and a residual pFXIII separates from the 
main peak. When fraction 3 was reloaded to the HPSEC a main peak centered at minute 
69 with a shoulder protruding at the leading edge (panel H). The SDS-PAGE shows the 
conformation of a complexed molecule in the leading edges fractions meanwhile the 
trailing edge.  
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Figure 3.3: High Pressure Size Exclusion, Panel A: γγ’ rF1 (solid line), pFXIII (dashed 
line), Panel B: γγ’ rF1 with pFXIII (10:1 mass ratio). Panel C: Non-reduced SDS-PAGE 
γγ’ rF1-pFXIII mixture. Lane 1: Fraction 1, Lane 2: Fraction 2, Lane 3: Fraction 3, Panel 
D: HPSEC fraction 1 Panel E: Non-reduced SDS-PAGE fraction 1 γγ’rF1-pFXIII 
mixture. Lane 1: fraction 1a, Lane 2: fraction 1b, Lane 3: fraction 1c, Panel F: HPSEC 
fraction 2 Panel G: Non-reduced SDS-PAGE fraction 2 γγ’rF1-pFXIII mixture. Lane 1: 
fraction 2a, Lane 2: fraction 2b, Lane 3: fraction 2c,  Panel H: HPSEC fraction 3 Panel 
I: Non-reduced SDS-PAGE fraction 3 γγ’rF1-pFXIII mixture. Lane 1: fraction 3a, Lane 
2: fraction 3b, Lane 3: fraction 3c.    
3.4.3. Peptide incorporation assay. The interactions between pFXIII and γγrF1 and 
γγ’rF1 were also investigated by the peptide incorporation assay. Figure 2.3 
shows the pFXIII activity in the collected fractions for the mixture γγrF1-pFXIII. 
Panel A shows that pFXIII activity is mostly localized in the HPSEC second peak 
that match the elution time for the pFXIII. The collected fractions 1, 2 and 3 were 
reloaded to the HPSEC system and the results presented in panel B, C and D. In 
panel B which corresponds to fraction 1, low levels of pFXIII activity is detected. 
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This low level of pFXIII activity indicates that pFXIII has a limited affinity for 
γγrF1. The Fraction 2 elution chromatogram presented in panel C shows 
maximum level of pFXIII activity in the second peak. This result confirmed that 
the γγrF1:pFXIII doesn’t form a complexed molecule instead most of the 
remaining pFXIII eluted along with γγrF1 during the first pass (fraction 2) is 
removed from the main peak and forms a protuberance that displays the no 
interaction. Panel D, mostly formed of the second peak in panel A, contains high 
level of pFXIII activity in all the collected fractions. The high level of pFXIII 
activity in this fraction indicates that most of the pFXIII is contained in this 
region. Even though some traces of pFXIII activity can be detected in previous 
HPSEC fractions this is not an indication of the formation of single complexed 
molecule but because of the closeness in the elution of γγrF1 and pFXIII some 
pFXIII are captured in the same collected fraction and apparently forming a single 
complexed molecule. 
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Figure 3.4: HPSEC and pFXIII activity (solid bars). Panel A: γγrF1 with pdFXIII (10:1 
molar ratio), Panel B: Fraction 1 HPSEC (second pass). Panel C: Fraction 2 HPSEC 
(second pass). Panel D: Fraction 3 (second pass). pFXIII activity estimated by peptide 
incorporation assay. 
In other hand, when γγ’rF1 is mixed with pFXIII, measureable levels of pFXIII 
are localized in throughout the chromatogram peak presented in panel A figure 2.4. 
Highest activity can be observed towards the center of the peak (875 U/mL). The 
collected factions were reloaded to the HPSEC system and the individual chromatograms 
presented in panel B, C, and D. Panel B is conformed of a single peak with pFXIII 
activity present in all the collected fractions. Same results are observed for fractions 2 
and 3 which are presented in panel C and D. As expected, these results presented in panel 
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A, B and C confirm the formation of a single complexed molecule which is mainly biased 
by the presence of the γ’ chain in the rF1. 
 
  
Figure 3.5: HPSEC and pFXIII activity (solid bars). Panel A: γγrF1 with pdFXIII (10:1 
molar ratio), Panel B: Fraction 1 HPSEC (second pass). Panel C: Fraction 2 HPSEC 
(second pass). Panel D: Fraction 3 (second pass). pFXIII activity estimated by peptide 
incorporation assay. 
3.4.4. HPSEC rFXIIIA: γγ and γγ’ rF1 interactions. In order to further explore the 
nature of the interactions between the γγ’rF1 and pFXIII, we mixed rFXIIIA with 
either γγ rF1 or γγ’rF1. The mixture was incubated for 1 hour at 37°C and the 
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elution chromatograms profile presented in figure 2.5. The standard elution 
profile for γγ rF1 and rFXIIIA are presented in panel A. Panel B represents the 
chromatogram profile for the γγ rF1 and pFXIII mixture. Two peaks were 
observed in the eluate which indicates the existence of two distinct and 
immiscible molecules that match exactly the elution time for the individual γγ rF1 
and rFXIIIA. Same result was observed when γγ’rF1 and rFXIIIA were mixed 
and incubated for 1 hour at 37°C (panel D).   
 
 
Figure 3.6: HPSEC, Panel A: γγrF1 (solid line), rFXIIIA (dashed line), Panel B: γγrF1 
with rFXIIIA (10:1 molar ratio), panel C: γγ’rF1 (solid line), rFXIIIA (dashed line). 
Panel D: γγ’rF1 with rFXIIIA (10:1 molar ratio). 
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3.4.5. DEAE γγrF1/γγ’rF1 pFXIII reconstitution. A mixture of rF1 (γγ/γγ’ 10:1) and 
pFXIII was loaded onto a DEAE sepharose and eluted as described in the 
methodology section. The elution chromatogram is presented in figure 2.7. Panel 
A shows the elution profile of the mixture pFXIII:rF1 (1:10). As expected, during 
the salt gradient profile elution two peaks were eluted resembling the γγ/γγ’ 
isolation of rF1. The pdFXIII added was contained on the second peak showing 
the grater affinity of pFXIII towards the acidic γ’ residue.  
     
Figure 3.7: DEAE-Sepharose chromatography of γγ/γγ’rF1 with the addition of 
pFXIIIA2B2. Samples were loaded onto a DEAE-Sepharose fast flow column (0.9 x 5 
cm) and eluted by gradient salt. Panel A: Elution profile of γγ/γγ’rF110:1 molar ratio. 
Panel B: pFXIII activity assayed by Biotin peptide incorporation. 
3.4.6. Dynamic Ligth Scattering. We used DLS to estimate the molecular size of the 
individual pFXIIIA2B2, γγrF1 and γγ’rF1and their mixtures γγrF1: pFXIIIA2B2 
and γγ’rF1:pFXIII. The hydrodynamic radius (RH) along with the percentage of 
polydispercity and the intensity percentage are presented in table 1. When 
pFXIIIA2B2 are mixed with either γγrF1 or γγ’rF1 the RH increases which may 
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indicate the natural interaction of pFXIII to γγrF1 and γγ’rF1. However the 
percentage of polydispercity which directly measures the heterogeneity of each 
species showed the heterogeneous composition of the γγ’rF1: pFXIIIA2B2 
mixture that indicates the existence of molecules of different sizes. The particle 
size distribution histogram presented in figure 2.8 confirmed that the addtion of 
pFXIIIA2B2 to γγ’rF1 contributes to the formation of high size molecules. 
 Table 3.1: γγ/γγ’rF1, pFXIII and mixture γγrF1:pFXIIIA2B2 and γγ’rF1: 
pFXIIIA2B2 Hydrodynamic radius (RH).  All samples were diluted into 
50mM TRIS, 115mM NaCl pH 7.5 (μ=0.15M) 
 Species RH (nm) Polydispercity % % Intensity 
γγ rF1 11.9 ± 0.3 20.6 ± 2.7 93.7  
γγ' rF1 11.8 ± 0.4 19.8 ± 2.1 97.9 
pFXIII 10.7 ± 0.4 24.7 ± 0.7 86.2 
γγrF1: pFXIIIA2B2 13.6 ± 0.3 26.7 ± 8.8 96.5 
γγ’rF1: pFXIIIA2B2 16.4 ± 1.5 48.1 ± 14.1 96.9 
 
 When γγrF1 is mixed with pFXIIIA2B2 the hydrodynamic radius increases up 
to 13.6 ± 0.3 nm. The particle size distribution histogram showed a prominent peak with 
an intensity distribution of 96.5%. The polydispersity of 26.7 indicates that the molecule 
is slightly polydisperse. In other hand, when γγ’rF1 is mixed with pFXIII the 
hydrodynamic radius increases up to 16.4 nm with an intensity percentage of 96.9. the 
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polydispercity indicates the high heterogeneity of the sample. The particle size 
distribution presented in panel D indicates the formation of high molecular size particles 
which can be due to some fibrinogen aggregation. In the same histogram, a prominent 
peak with a radius of 40.1nm indicates the existence of particles of high molecular size.  
       
             
 
Figure 3.8: particle distibution histogram. Panel A: γγrF1, panel B: γγrF1: pFXIIIA2B2, 
panel C: γγ’rF1 panel D: γγ’rF1: pFXIIIA2B2, panel E: pFXIIIA2B2. 
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3.5. Discussion 
Previous studies focused on the interaction between pFXIIIA2B2 and the two major 
species of pdF1, γγ and γγ’, suggested that the γ’ chain was responsible for the interaction 
with pFXIIIA2B2 via B subunit. However inconsistent results led to discrepancies about 
the role of γ’ as the primary binding site for the zymogen pFXIIIA2B2. We suspect that 
many of those inconsistencies arose from the fact that fibrinogen preparations from 
normal human plasma content traces of pFXIIIA2B2 as we assessed our pF1 preparations 
by western blot 9 (data not shown).  In fact, Farrell pointed out that the discrepancies 
between his results and Siebenlist’s group were due to the uncounted pFXIII bound onto 
the γγ’pF1 preparations which induced the high rate of crosslink when compared with 
that of γγpF1 [32]. In order to avoid misleading results, we used rF1 expressed in milk of 
transgenic cows which is free factor XIII and possess same activation kinetics and rate of 
polymerization as the of pF1. [7]  In our studies, we employed size exclusion 
chromatographic techniques and dynamic light scattering to assess the binding of the 
zymogen pFXIIIA2B2 to the major fibrinogen variants γγ and γγ’ isolated from 
recombinant fibrinogen. 
In our experiments, we observed that the γ’ chain is the main peptide responsible for 
the interactions with the zymogen pFXIIIA2B2. The tendency of pFXIIIA2B2 to migrate 
towards the γγ’rF1 position when analyzed by HPSEC showed the intrinsic affinity 
between these molecules. This results were in clear concordance with Siebenlist’s work 
as they reported the formation of a single peak when a mixture of 25mg γγ’pF1 and 5mg 
pFXIIIA2B2 were loaded onto a pair of Superose 6 size exclusion columns. [1] However 
55 
 
in order to confirm the pFXIIIA2B2:γγ’rF1 complex formation, the collected the fractions 
from the pFXIIIA2B2:γγ’rF1 eluate were reloaded onto the Superose 6 HPSEC system to 
confirm the existence of a single species. In fact, we observed that each fraction eludes as 
a single peak. The non-reduced SDS-PAGE analysis of each peak conforms the 
coexistence of pFXIIIA2B2 and γγ’rF1 as a single complex molecule. In addition, the 
factor XIII activity determined by the peptide incorporation assay showed that each 
collected pFXIIIA2B2:γγ’rF1 fraction contain high levels of FXIII activity which reaffirm 
the pFXIIIA2B2 incorporation into the γ’ chain.  
Based on results reported by Moaddel [22] and Siebenlist [20], it is expected to 
observe no interaction between pFXIIIA2B2 and γγrF1, however our HPSEC experiments 
determined that there’s not complete dissociation of the mixture pFXIIIA2B2 and γγrF1 
what can be assumed that exits some level of interaction that creates an incomplete 
integration of both pFXIIIA2B2 and γγrF1. In order to elucidate a possible interaction 
between pFXIIIA2B2 and γγrF1, we reloaded the collected eluate fractions to the HPSEC 
system. Our results indicated the formation of a single peak which confirms the existence 
of the complex pFXIIIA2B2:γγrF1. In addition, the FXIII activity assay showed low level 
of activity compared with the of pFXIIIA2B2:γγ’rF1. We assume that this level of activity 
is related to a low binding affinity of pFXIIIA2B2 to γγrF1. In fact, Byrnes determined 
that the γ chain amino acids 390-396 are key residues that act as binding site for the 
zymogen pFXIIIA2B2. [21] In addition, Smith constructed recombinant truncations of the 
fibrinogen αC region and identified a high affinity interaction between pFXIIIA2B2 and 
amino acid residues localized in the αC region 371-425. [20] Even though those findings 
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suggest the high affinity between the zymogen pFXIIIA2B2 and the γ and αC chains, our 
results demonstrated that pFXIIIA2B2 may have a low binding affinity to both α the γ 
chain as the majority of the pFXIIIA2B2 is displaced forming a second peak as observed 
in figure 2.2 panel B. This suggestion is supported by our analysis of the pFXIII 
incorporation peptide assay in which high level of pFXIII activity is located in the second 
peak. 
We also investigated the binding of the factor XIII A-subunit to γγ and γγ’ rF1. As 
showed in the HPSEC profile for the mixtures rFXIIIA1-γγ’rF1 and rFXIIIA1:γγrF1, no 
binding was observed what suggest that this interaction depends exclusively on the FXIII 
B subunit. Our results are in total agreement with the reports presented by Siebenlist, [1] 
Moaddel [22] and Byrnes [21] who performed an extensive evaluation of this interaction.  
Although all previous experiments presented here showed an intrinsic interaction 
between pFXIII and either γγrF1 or γγ’rF1, chromatographic technique do not provide 
information about the structural rearrangements during the formation of the complexes. 
Our DLS experiments showed that HPSEC isolated γγrF1, γγ’rF1 and pFXIIIA2B2 
samples exhibited monodisperse behavior which agrees with previous results presented 
by Huang & Lord. [33] However when mixed the percentage of polydispersity increases 
which indicated the existence of particles of different sizes. In previous studies, 
Wasilewska who assessed the fibrinogen RH under different pH values observed the rapid 
increase of the RH induced by the formation of aggregates as the value approaches to the 
fibrinogen isoelectric point (i.p 5.8). [23] In our studies we maintained a constant pH of 
7.5 which leaves pFXIIIA2B2 as the only protein with the ability to form complexes with 
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γγrF1 and γγ’rF1. As presented in our results, we might suggest that the 
pFXIIIA2B2:γγ’rF1 mixture has a higher tendency to form complexes as the percentage of 
polydispercity increases which indicates the presence of larger complexed particles with 
flexible arrangements.   
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CHAPTER IV 
The plasma factor XIII activation is regulated by the γγ’ fibrinogen chain 
4.1. Summary 
In the presence of Factor XIII cross-linking activity, the process of fibrinogen 
polymerization rapidly proceeds from a short-lived soluble phase initiated at low 
viscosity, to within a semi-soluble and partially cross-linked fibrin hydrogel environment, 
to a highly cross-linked totally insoluble viscoelastic solid. Thus, the reactions occur 
mostly in a heterologous manner with restricted mass transfer from the liquid phase and 
where most enzymatic reactions are occurring entirely within the evolving aqueous 
hydrogel polymer phase. The high level reaction efficiency that can occur within the 
fibrin hydrogel are seen by thromboelastography in the presence of higher levels of 
thrombin and Factor XIII enzyme activity that almost instantly catalyze the formation of 
a thoroughly dense, cross-linked viscoelastic fibrin polymer. This efficiency is essential 
to rapidly re-establishing hemostasis under threatening conditions of hemorrhage.  
In this chapter, we assessed the effect of the two major variants of a recombinant 
fibrinogen (rFI) and fibrin (rFbn) γγ and γγ’ on the rate of pFXIIIa2b2 activation.  This 
provides information about how a rF1 fundamentally interacts with FXIII and an 
advantage of evaluating FXIII interactions in the absence  of a fibrinogen having no 
endogenous Factor XIII activity.  It is noted that plasma-derived fibrinogen contains 
complexed Factor XIII which complicates evaluation of subtle kinetic interactions with 
fibrinogen and exogenously added Factor XIII activity.  Two advantages Three main 
stages that resembled the activation mechanism of pFXIIIa2b2 were studied using a 5-
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(biotinamino pentylamine) peptide incorporation assay which permits the analysis of 
heterologous reactions occurring within a solid phase containing an immobilized 
fibrinogen species. Thus, the liquid phase solutions containing (A) the non-active 
tetramer (pFXIIIa2b2), (B) the thrombin cleaved (pFXIIIa2’b2) and (C) the thrombin 
cleaved non-active dimeric plasma factor XIII a-subunit (pFXIIIa2’) were individually 
place in contact with a previously immobilized γγ, γγ’ rFI or γγ, γγ’ rFbn (immobilized 
solid phase).  This heterologous setting allows the evaluation of the effect of fibrinogen 
and fibrin (solid phase) on the rate of pFXIIIa2b2 activation (delivered from the liquid 
phase). In general, the results indicated that the presence of γγ or γγ’ rFbn increased the 
rate of pFXIIIa2* generation when compared with that of γγ or γγ’ rFI. A detailed 
analysis for each stage suggested that in “stage I” γγ’rFbn enhances the rate of proteolytic 
activation of pFXIIIa2b2 yielding pFXIIIa2’b2. It is consistent with past reports of the 
γγ’rFbn induction of the formation of a ternary molecular complex between Fbn, 
thrombin and pFXIIIa2b2 that results in the enzymatic removal of the pFXIIIa2b2 
activation peptide. In “stage II”, the pFXIIIa2’b2 dimeric dissociation into pFXIII-A2 and 
pFXIII-B2 subunits was expedited by the presence of the γγ’rFbn which interacts with 
pFXIII-B2 subunit. However when pFXIIIa2’ was incubated with either γγ or γγ’ rFI and 
rFbn, no significance difference on the rate of pFXIIIa2* generated was observed 
suggesting that the γγ’rFbn enhances the rate of pFXIIIa2b2 activation. From this we 
conclude that the enzymatic activation of the tetramer plasma factor XIII (pFXIIIa2b2) is 
regulated by the γγ’ fibrin variant which operates as both substrate and cofactor. The γγ’ 
fibrin modulates the thrombin enzymatic cleavage of the factor XIII activation peptide 
and accelerates the rate of the factor XIII B-subunit dissociation. 
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4.2. Introduction 
Whether in solution in the short-lived absence of fibrin polymer hydrogel or 
within the evolving fibrin polymer hydrogel, the active transglutaminase plasma factor 
XIII (pFXIIIa2*) is generated from the zymogen plasma factor XIII (pFXIIIa2b2) which 
undergoes proteolytic and conformational modifications to expose its catalytic core. [1, 
2] The pFXIIIa2b2 activation mechanism, as presented in Scheme A, consists of a series 
of sequential step that can be divided in 3 main stages [3, 4]. In the first stage, thrombin 
removes a 4kDa factor XIII activation peptide (APFXIII) from the N-terminal of the A 
subunit (83kDa) yielding the non-active thrombin cleaved factor XIII (pFXIIIa2’b2) [5, 
6]. Subsequently, pFXIIIa2’b2 dissociates into two A and two B subunits in the presence 
of fibrin/fibrinogen and Ca
2+
 at physiological levels [7, 8]. In the final stage, pFXIIIa2’ 
undergoes conformational changes to form the fully active factor XIII (pFXIIIa2*) which 
catalyzes formation of the γ-glutamyl–ε-lysyl peptide cross link between adjacent 
glutamine–lysine residues in the γ and α chains of fibrin units.  [9, 10, 11, 12].  
𝐹𝑋𝐼𝐼𝐼 𝑎2𝑏2    
      𝑟𝐹𝐼𝐼𝑎    
↔          𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 +𝐴𝑃𝐹𝑋𝐼𝐼𝐼                                 [Stage I] 
𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2    
      𝐶𝑎2+ ,   𝐹𝑖𝑏𝑟𝑖𝑛𝑜𝑔𝑒𝑛/𝐹𝑖𝑏𝑟𝑖𝑛    
↔                          𝐹𝑋𝐼𝐼𝐼 𝑎2
′  +  𝐹𝑋𝐼𝐼𝐼𝑏2      [Stage II] 
𝐹𝑋𝐼𝐼𝐼 𝑎2′   
      𝐶𝑎2+ ,   𝐹𝑖𝑏𝑟𝑖𝑛𝑜𝑔𝑒𝑛/𝐹𝑖𝑏𝑟𝑖𝑛    
↔                          𝐹𝑋𝐼𝐼𝐼 𝑎2
∗                               [Stage III] 
Scheme A: The overall pFXIIIa2b2 activation mechanism in the presence of thrombin, 
FI/Fbn and Ca
2+
 at physiological levels. 
The factor XIII catalytic core domain is conformed of both β-cheets and α helices. 
This domain contains the catalytic triad comprising Cys 314, His 373 and Asp 396 that 
interact with each other through a hydrogen bonding network. [13, 14] The factor XIII 
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transamidation reaction mechanism (Scheme B) begins by the recognition of the 
glutamine residues followed by a nucleophilic attack of the thiolate sulfur Cys 314 to the 
side chain of the glutamine residue. Then, the formation of a thioester bond is achieved 
by the release of ammonia from glutamine forming an acyl glutamil residue. The 
following step consists of the binding of the enzyme-substrate complex to a primary 
amine from a lysine residue. Because of the high reactivity of the thioester group the 
formation of the isopeptide bond occurs rapidly. [15, 16] 
    
    
            
Scheme B: transglutaminase reaction mechanism of the enzyme factor XIII. Gln and Lys 
are the residues in fibrin monomers. 
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Studies on the pFXIIIa2b2 activation mechanism suggested that generation of 
pFXIIIa2* is regulated by the presence of fibrin. In particular, the γγ’ fibrinogen variant 
which represent about 10% of the total normal fibrinogen was reported to interact with 
the pFXIII-B subunit and thrombin forming a termolecular complex that expedite the 
cleavage of the APFXIII. [3, 2, 13, 14, 15]In addition, the γ’-pFXIII-B subunit interaction 
facilitates the pFXIIIa2b2 subunit dissociation increasing the rate of pFXIIIa2* formation. 
[16, 17] Further investigations suggested that pFXIIIa2* formation is regulated by 
fragments derived from the fibrin plasmin degradation emerging from the midsection of 
the α chain. It was also suggested that fibrinogen residues in the γ chain regulate the 
pFXIIIa2b2 activation in a pFXIIIb2 dependent mechanism. These observations proposed 
that fibrinogen and/or fibrin acts a cofactor during the pFXIIIa2b2 activation and provide 
regulation for the pFXIIIa2* catalysis. [5] 
The transglutaminase kinetic behavior of pFXIIIa2* was found to be in accord with a 
ping-pong mechanism as suggested by Chung and Folk. (Scheme B) [18]In their study, 
the isotope exchange method was used to define the pFXIIIa2b2 reaction pathway in the 
absence of one or more reactants. However in order to estimate kinetic constant (Kd. Kcat, 
Km), a simplified sequential activation pathway scheme was proposed by Shafer’s group. 
They reported that fibrinogen and fibrin are required to promote the release of APFXIII and 
lower the Km value. [4]  
In an effort to reconcile previous studies and present new evidence on the effect of 
fibrinogen in the pFXIIIa2b2 activation mechanism, we recreated the 3 main stages of the 
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pFXIIIa2b2 activation process to identify the stage at which the γγ and γγ’ variants of 
fibrinogen and fibrin exert the co-factor effect in the pFXIIIa2b2 activation mechanism.  
4.3. Materials and Methods 
All reagents were purchased from Fisher Scientific unless otherwise stated. 5-
Biotinamide pentylamine (5bapa) was obtained from Thermo Scientific. D-Phe-Pro-Arg-
CMK-HCl (PPACK) was acquired from HaemTech Inc. (VT), p-Nitrophenyl phosphate 
(pNPP) tablets and Streptavidin-Alkaline phosphatase was purchased from Sigma Life 
Science. DL-Dithiothreitol (DTT), Diethanolamine and Albumin from Bovine Serum 
(BSA) were acquired from Sigma-Aldrich. High Binding microtiter plates were 
purchased from FisherScientific. Rabbit monoclonal Anti-Factor XIIIA subunit antibody 
and murine monoclonal Anti-Factor XIIIB subunit was purchased from abcam (ab79759) 
and green mountains antibodies (GMA-033) respectively. 
4.3.1. Plasma factor XIII, (pFXIIIa2b2) was purchased from Enzyme Research 
Laboratories (IN). The pFXIIIa2b2 was diluted to concentrations ranging from 
5nM to 21nM for microtiter plate assay. Thrombin cleaved pFXIIIa2’b2 was 
prepared by incubating pFXIIIa2b2 with 1.1 NIH U/mL rFIIa for 15 minutes and 
isolated by size exclusion chromatography (SEC) using TRIS buffer with 115mM 
NaCl pH7.5. In the same manner, the thrombin cleaved dimeric A subunit 
pFXIIIa2’ was prepared by incubating pFXIIIa2b2 with 1.5 NIH U/mL and 30mM 
of CaCl2 for 15 minutes. Then pFXIIIa2’ was isolated by size exclusion 
chromatography (SEC) Finally, the fully active pFXIIIa2* was prepared by 
incubating pFXIIIa2b2 with both 1.1 NIH U/mL and 30mM CaCl2. The solution 
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was added to immobilize fibrin or fibrinogen in microtiter plate to a final 
concentration of 1.1mM CaCl2.  
4.3.2. Monomeric recombinant factor XIII (rFXIIIA) was intracellular expressed in 
the yeast Pichia pastoris X-33 as previously described [19]. rFXIIIA was purified 
in a His-Bind® nickel charged resin column.  
4.3.3. γγ and γγ recombinant fibrinogen (rFI). rFI was expressed in the milk of 
transgenic dairy cows and purified by a two-column purification procedure using 
cation exchange (CIEX) and hydrophobic interaction chromatography (HIC) [20]. 
The γγ and γγ rF1 isolation was carried out in a weak anion exchange DEAE 
Sepharose™ Fast Flow column by pH gradient as previously described [14]. 
4.3.4. Recombinant activated thrombin (rFIIa) was purchased from Zymogenetics 
(WA). 1000U/mL aliquots were prepared in 0.9% NaCl and stored at -80 ⁰C. 
4.3.5. Factor XIII 5-Biotinamino-pentylamine (5-bapa) incorporation activity 
assay. The factor XIII mediated incorporation of biotinamino-pentylamine to γγ 
or γγ’ rF1 was determined using an assay adapted from a previously developed 5 
biotionamido-pentylamine (5-bapa) assay. [21, 22, 23] In general, 100 μL of 
40μg/mL of γγ or γγ’rF1 were poured into each well of a 96 high binding 
microtiter plate. Then plates were incubated for 1 hour at 37°C. Blocking buffer 
(1%BSA in TBS) was added to the wells and incubated overnight at room 
temperature. To evaluate the effect of fibrinogen (FI) and fibrin (Fbn) in the 
assay, the adsorbed FI was converted to fbn by adding 100μL of 1.11 NIH U/mL 
rFIIa. Then, 50μL of crosslink substrate mix (0.25mM 5bapa, 0.1mM DTT and 
1.1 mM CaCl2) was added to each well and incubated for 10 minutes at room 
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temperature. To evaluate the effect of γγ and γγ’ FI and Fbn, 4 different settings 
that resemble the pFXIIIa2b2 activation stages were prepared as indicated in the 
pFXIIIa2b2 section. Then 50μL of either pFXIIIa2b2, pFXIIIa2’b2, pFXIIIa2 or 
pFXIIIa2* was added to each well and the plate was incubated for 30 minutes at 
room temperature. 200μL of 200mM EDTA were added to each well to quench 
transglutaminase reaction. The same procedure without previous conversion to 
fibrin was followed when fibrinogen was immobilized in wells. Then, 100μL of 
2.0 μg/mL Streptavidin alkaline phosphatase solution was added to each well and 
incubated at 37⁰C for 1 hour. After incubation, plates were washed and 100μL of 
para-nitrophenyl phosphate (p-NPP) dissolved in 1M Diethanoalamine was added 
to the wells. The color developing (clear to yellow) indicated the phosphatase 
activity on the p-NPP substrate. Finally, the reaction was stopped by adding 
200μL of 4N NaOH after 2 minutes reaction. The plates were read at 405nm using 
Beckman Coulter AD340 plate reader. The results were expressed in units of 
optical density. 
4.3.6. Estimation of kinetic constants: Michaelis-Menten (KM) and Maximal 
Velocity (Vmax). The 5-BAPA incorporation activity assay was used to estimate 
the kinetic constants Michaelis-Menten (KM) and maximal velocity (Vmax). A 
proposed reaction mechanism is presented in Scheme B1 as suggested by et.al. 
Chung. In order to estimate the kinetic constants, the reaction mechanism 
presented in Scheme B1 was linearized (Scheme B2). Further reduction of the 
reaction mechanism in scheme B2 is obtained by assuming high concentration of 
factor XIII (E) and fibrin (F) and the pre activation of both fibrinogen to fibrin 
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and factor XIII (pFXIIIa2b2) to active factor XIII (pFXIIIa2’). Scheme B3 shows 
the reaction mechanism proposed for the estimation of the kinetic constants KM 
and Vmax. Algebraic deduction of the main equations for KM and Vmax 
estimation is presented in scheme C. 
 
 
 
 
Scheme C: Transglutaminase reaction mechanism suggesting the incorporation of the 
Biotin peptide. In short, the active transglutaminase FXIII (pFXIIIa2’) acts on the fibrin 
glutamine residues inducing deamination and formation of glutamyl acyl residue. Thus, 
Gln residue behaves as acyl donor. Then, the 5BAPA, that simulates a Lysine residue, is 
integrated to the glutamyl acyl residue previous deamination. The Lys like chain 
C1 
C2 
C3 
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incorporated to the Biotin resemble the acyl group receptor. Finally, s ternary complex is 
formed by є (γ-glutamyl) Lysine crosslink.  (C2) Linearized reaction mechanism of C1. 
(C3) Simplified reaction mechanism considering high concentration of Fibrin (F) and 
factor XIII (E). 
Estimation of KM and Vmax were possible by changing the concentration of the 
Biotin peptide on the microtiter plate. Concentrations of 5BAPA were in the range of 
0.25 to 2.5 mM and incubated for 0.5 to 15 minutes. In order to obtain quantifiable data, 
each reaction was performed in triplicate. The averaged values were used to construct a 
Reaction Time vs Absorbance plot. Fitted linear regression equations were obtained for 
each of the plotted lines and used to estimate the initial velocity (Vo). Inverse values of 
both Vo and substrate concentration (S) were used to prepare the Lineweaver Burk plot. 
Experimental values obtained from the proposed reaction mechanism were used to 
estimate Vmax and Km.  
 
[EF*B] = K2 [EF*] + [B] 
Total enzyme coupled with fibrin monomer ETF* 
[ETF*] = [EF*] + [EF*B] 
[EF*]  = [ETF*] – [EF*B] 
 [EF*B] = K2 [B] ([ETF*] – [EF*B]) 
[EF*B] = K -2 [EF*B] – K3 [EF*B] 
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Then: K -2 [EF*B] –  K3 [EF*B] = K2 [B] [ETF*] – K2 [EF*B] [B] 
[E𝐹∗B] =  
𝑘2 [B] [𝐸𝑇F
∗] 
𝑘−2 + 𝑘3 + 𝑘2[𝐵]
 
Then: 
Vmax = k3 [ETF*] 
[EF*B] = Vo/k3 
𝐾𝑚 = 
𝑘−2 + 𝑘3
𝑘2
 
 𝑉𝑜 =
𝑉𝑚𝑎𝑥 [𝐵]
𝐾𝑚+[𝐵]
 
Scheme D: Algebraic representation of the equation used to estimate Km and Vmax. 
4.3.7. High Pressure Size Exclusion Chromatography. (HPSEC) Mixtures of 
pFXIIIa2b2 and fibrinogen (γγ or γγ’) were prepared in 50mM Tris buffer, 115 
mM NaCl, pH 7.5 maintaining ionic strength of 0.15. The mixtures were loaded 
into two superose 6 10/300 (GE lifescience) columns connected in series to a 
Knauer (Berlin, Germany) Smartline chromatography station. The columns were 
isocratically eluted using Tris Buffer at a flow rate of 0.50 mL/min and the length 
of the run was 90 minutes. Effluent’s absorbance was read at 280nm and collected 
fractions were assayed for Factor XIII activity and SDS-Page. 
4.3.8. SDS PAGE gel electrophoresis. Non-reduced and reduced samples of pFXIII, γγ 
and γγ’rF and their mixtures were evaluated by sodium dodecylsulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% NuPage Bis-Tris pre-
cast gels (Thermofisher, CA). All the gels ran for 1 hour at 200 volts and then 
stained with colloidal Blue gel stain (Invitrogen, CA, USA).  
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4.4. Results 
We evaluated the effect of the two major variants, γγ and γγ’, of a recombinant 
fibrinogen and recombinant fibrin on the three stages of the pFXIIIa2b2 activation using 
the peptide incorporation microtiter plate assay.  Previous Studies determined that fibrin 
acts as both substrate and cofactor during the pFXIIIa2b2 activation suggesting the 
formation of a termolecular complex fibrin-thrombin- FXIIIa2b2 which enhances the 
cleavage of the factor XIII activation peptide (APFXIII) and promotes the generation of 
pFXIIIa2’b2. [2, 28] Further investigations indicates that the non-covalent binding of 
pFXIIIa2b2 to the fibrinogen γ’ variant increases the rate of pFXIIIa2b2 activation by 
accelerating the rate of B subunit dissociation. [5] Although these past investigations 
provides convincing information about the pFXIIIa2b2 activation mechanism, it is 
unknown the stage at which the γγ or γγ’ variants have higher influence over the 
pFXIIIa2b2 activation. In our study, we recreated the main 3 stages of the pFXIIIa2b2 
activation in the presence or absence of γγ and γγ’ FI and Fbn. Schemes E to F represent 
the different stages of pFXIIIa2b2 activation. 
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a) pFXIIIa2b2 – γγ Fibrinogen  
[𝜶𝜷]𝟐𝜸𝜸 + 𝐹𝑋𝐼𝐼𝐼 𝑎2𝑏2 + 𝑟𝐹𝐼𝐼𝑎  
               
↔     𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵  
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂  
                
↔      𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸 + 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼   
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸 + 𝒓𝑭𝑰𝑰𝒂 
      1.1𝑚𝑀 𝐶𝑎𝐶𝑙2          
↔                 𝑭𝑿𝑰𝑰𝑰 𝒂𝟐
∗ • [𝜶∗𝜷]𝟐𝜸𝜸 − 𝑨𝒈+ 𝒓𝑭𝑰𝑰𝒂 + 𝒃𝟐 
b) pFXIIIa2b2 – γγ’ Fibrinogen  
[𝜶𝜷]𝟐𝜸𝜸′ + 𝐹𝑋𝐼𝐼𝐼 𝑎2𝑏2 + 𝑟𝐹𝐼𝐼𝑎  
               
↔     𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵  
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂  
                
↔      𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ + 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼   
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ + 𝒓𝑭𝑰𝑰𝒂 
      1.1𝑚𝑀 𝐶𝑎𝐶𝑙2          
↔                 𝑭𝑿𝑰𝑰𝑰 𝒂𝟐
∗ • [𝜶∗𝜷]𝟐𝜸𝜸′ − 𝑨𝒈+ 𝒓𝑭𝑰𝑰𝒂 + 𝒃𝟐 
 
c) pFXIIIa2b2 – γγ Fibrin  
[𝛼𝛽]2𝛾𝛾  
      𝑟𝐹𝐼𝐼𝑎      
↔           [𝜶∗𝜷]𝟐𝜸𝜸 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵 
[𝜶∗𝜷]𝟐𝜸𝜸 + 𝐹𝑋𝐼𝐼𝐼 𝑎2𝑏2 + 𝑟𝐹𝐼𝐼𝑎  
                      
↔        𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂 
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂  
                          
↔         𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸+ 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼  
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸 + 𝑟𝐹𝐼𝐼𝑎
         1.1𝑚𝑀 𝐶𝑎𝐶𝑙2           
↔               𝑭𝑿𝑰𝑰𝑰 𝒂𝟐
∗ • [𝜶∗𝜷]𝟐𝜸𝜸 − 𝑨𝒈+ 𝑟𝐹𝐼𝐼𝑎 + 𝑏2 
d) pFXIIIa2b2 – γγ’ Fibrin  
[𝛼𝛽]2𝛾𝛾′  
      𝑟𝐹𝐼𝐼𝑎      
↔           [𝜶∗𝜷]𝟐𝜸𝜸+ 𝑓𝑝𝐴 + 𝑓𝑝𝐵 
 
[𝜶∗𝜷]𝟐𝜸𝜸′ + 𝐹𝑋𝐼𝐼𝐼 𝑎2𝑏2 + 𝑟𝐹𝐼𝐼𝑎  
                      
↔        𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂 
 
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂  
                          
↔         𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ + 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼  
 
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐′𝒃𝟐 • [𝜶
∗𝜷]𝟐𝜸𝜸′ + 𝑟𝐹𝐼𝐼𝑎
         1.1𝑚𝑀 𝐶𝑎𝐶𝑙2           
↔               𝑭𝑿𝑰𝑰𝑰 𝒂𝟐
∗ • [𝜶∗𝜷]𝟐𝜸𝜸 − 𝑨𝒈+ 𝑟𝐹𝐼𝐼𝑎
+ 𝑏2 
Scheme E: pFXIIIa2b2  activation pathway in the presence of : a) γγ Fibrinogen  b) γγ’ 
Fibrinogen  c) γγ Fibrin d) γγ’ Fibrin.  
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𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2𝑏2    
      𝑟𝐹𝐼𝐼𝑎    
↔          𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼                          
 
a) pFXIIIa2’b2 – γγ Fibrinogen  
[𝛼𝛽]2𝛾𝛾 + 𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 + 𝑟𝐹𝐼𝐼𝑎  
                         
↔         𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 • [𝛼
∗𝛽]2𝛾𝛾 + 𝑟𝐹𝐼𝐼𝑎 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵  
𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 • [𝛼
∗𝛽]2𝛾𝛾 + 𝑟𝐹𝐼𝐼𝑎
       1.5𝑚𝑀 𝐶𝑎𝐶𝑙2         
↔                 𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾 − 𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎 + 𝑏2  
 
b) pFXIIIa2’b2 – γγ’ Fibrinogen  
[𝛼𝛽]2𝛾𝛾′ + 𝐹𝑋𝐼𝐼𝐼𝑎2′𝑏2 + 𝑟𝐹𝐼𝐼𝑎  
                        
↔         𝐹𝑋𝐼𝐼𝐼𝑎2′𝑏2 • [𝛼
∗𝛽]2𝛾𝛾
′ + 𝑟𝐹𝐼𝐼𝑎 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵 
𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 • [𝛼
∗𝛽]2𝛾𝛾
′ + 𝑟𝐹𝐼𝐼𝑎  
      1.5𝑚𝑀 𝐶𝑎𝐶𝑙2          
↔                 𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾
′ −𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎 + 𝑏2  
 
c) pFXIIIa2’b2 – γγ’ Fibrin  
[𝛼𝛽]2𝛾𝛾   
      𝑟𝐹𝐼𝐼𝑎        
↔           [𝛼∗𝛽]2𝛾𝛾 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵 
[𝛼∗𝛽]2𝛾𝛾 +  𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2   
                      
↔          𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 • [𝛼
∗𝛽]2𝛾𝛾  
       1.5𝑚𝑀 𝐶𝑎𝐶𝑙2     
↔            𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾
− 𝐴𝑔   +  𝑏2 
 
d) pFXIIIa2’b2 – γγ’ Fibrin 
[𝛼𝛽]2𝛾𝛾
′  
      𝑟𝐹𝐼𝐼𝑎    
↔          [𝛼∗𝛽]2𝛾𝛾′ + 𝑓𝑝𝐴 + 𝑓𝑝𝐵 
[𝛼∗𝛽]2𝛾𝛾′ +  𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2   
                      
↔          𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 • [𝛼
∗𝛽]2𝛾𝛾
′
     1.5𝑚𝑀 𝐶𝑎𝐶𝑙2     
↔            𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾
′ − 𝐴𝑔 
+ 𝑏2 
 
Scheme F: pFXIIIa2’b2  activation pathway in the presence of : a) γγ Fibrinogen  b) γγ’ 
Fibrinogen  c) γγ Fibrin d) γγ’ Fibrin.  
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𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2𝑏2    
      𝑟𝐹𝐼𝐼𝑎    
↔          𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼                          
𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2′𝑏2    
      𝑟𝐹𝐼𝐼𝑎    
↔          𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2′ + 𝑏2        
a) pFXIIIa2’b2 – γγ Fibrinogen 
 
𝐹𝑋𝐼𝐼𝐼 𝑎2′ + [𝛼 𝛽]2𝛾𝛾 + 𝑟𝐹𝐼𝐼𝑎
       1.5𝑚𝑀 𝐶𝑎𝐶𝑙2         
↔                 𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾 − 𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎  
 
b) pFXIIIa2’b2 – γγ’ Fibrinogen  
𝐹𝑋𝐼𝐼𝐼 𝑎2′ + [𝛼
∗𝛽]2𝛾𝛾
′ + 𝑟𝐹𝐼𝐼𝑎  
      1.5𝑚𝑀 𝐶𝑎𝐶𝑙2          
↔                 𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾
′ −𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎  
 
c) pFXIIIa2’b2 – γγ’ Fibrin  
[𝛼𝛽]2𝛾𝛾   
      𝑟𝐹𝐼𝐼𝑎        
↔           [𝛼∗𝛽]2𝛾𝛾 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵 
[𝛼∗𝛽]2𝛾𝛾 +  𝐹𝑋𝐼𝐼𝐼 𝑎2′  
                      
↔          𝐹𝑋𝐼𝐼𝐼 𝑎2′ • [𝛼
∗𝛽]2𝛾𝛾  
       1.5𝑚𝑀 𝐶𝑎𝐶𝑙2     
↔            𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾 − 𝐴𝑔 
 
d) pFXIIIa2’b2 – γγ’ Fibrin 
[𝛼𝛽]2𝛾𝛾
′  
      𝑟𝐹𝐼𝐼𝑎    
↔          [𝛼∗𝛽]2𝛾𝛾′ + 𝑓𝑝𝐴 + 𝑓𝑝𝐵 
[𝛼∗𝛽]2𝛾𝛾′ +  𝐹𝑋𝐼𝐼𝐼 𝑎2′  
                      
↔          𝐹𝑋𝐼𝐼𝐼 𝑎2′ • [𝛼
∗𝛽]2𝛾𝛾
′
     1.5𝑚𝑀 𝐶𝑎𝐶𝑙2     
↔            𝐹𝑋𝐼𝐼𝐼 𝑎2
∗ • [𝛼∗𝛽]2𝛾𝛾
′ −𝐴𝑔 
 
Scheme G: pFXIIIa2’  activation pathway in the presence of : a) γγ Fibrinogen  b) γγ’ 
Fibrinogen  c) γγ Fibrin d) γγ’ Fibrin.  
4.4.1. γγ’rFbn promotes the Activation peptide FXIII (APFXIII) cleavage . We tested 
the hypothesis that the APFXIII cleavage is accelerated by the formation of a 
termolecular complex between pFXIIIa2b2, rFIIa and either γγ or γγ’ rFbn. 
Scheme E summaries the reactions steps that includes the formation of a 
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termolecular complex previous to the generation of pFXIIIa2*. Figure 1, panel A 
and B, presents the results of the 5-bapa peptide incorporation assay after 
incubating γγ, γγ’rFI or γγ, γγ’rFbn with 1.5 U/mL active recombinant thrombin 
(rFIIa) from 0.5 to 15 minutes. The X axis showed the thrombin incubation time 
quenched by the addition of 1.0mM PPACK. We observed that both γγ and γγ’ 
rFbn increased the generation of pFXIIIa2* when compared with that of γγ and γγ’ 
rFI. However, the rate of pFXIIIa2* formation was particularly enhanced by the 
presence of γγ’rFbn in the mixture. As presented in figure 1B, after 5 minutes of 
rFIIa incubation the absorbance signal at 405nm exhibited an increase of 
approximate 23% when γγ’rFbn is compared to γγ rFbn. Furthermore, a 37% 
increase on the absorbance signal was observed when γγ’rFbn is compared to the 
γγ’rFI. In other hand, our experiments using either γγ or γγ’ rFI, figure 1 panel A, 
indicated that γγ’rFI enhanced the generation of pFXIIIa2* by only approximately 
8.0% when compared with that of γγrFI.  
   
Figure 4.1: pFXIIIa2b2  activation kinetics by r-α Thrombin in the presence of: (■) γγ’rFI, 
(□) γγrFI, (●) γγ’rFbn, (○) γγ rFbn.  
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4.4.2. The γγ’ increases the rate of pFXIIIa2* generation by enhancing the B 
subunit dissociation. In addition to our results presented in Figure 1, we assessed 
the effect of the pFXIIIb2 – γ’ chain non-covalent interaction in the rate of 
pFXIIIa2* generation. To evaluated this effect, we tested the pFXIIIa2’b2 and 
pFXIIIa2’ along with γγ, γγ’ rFI and rFbn using the peptide incorporation 
microtiter plate assay.  
        
 
Figure 4.2: pFXIIIa2’b2  activation kinetics in the presence of: A) (■) γγ’rFI, (□) γγrFI, 
B) (●) γγ’rFbn, (○) γγrFbn. C) Bar diagram representing signal absorbance at 405nm. 
Bars are means ± SD, N=6. 
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Figure 4.3: pFXIIIa2’  activation kinetics in the presence of: A) (■) γγ’rFI, (□) γγrFI, B) 
(●) γγ’rFbn, (○) γγrFbn. C) Bar diagram representing signal absorbance at 405nm. Bars 
are means ± SD, N=6. 
Scheme E and F summarize the suggested steps for pFXIIIa2* generation and the 
results are presented in figure 4.2 and 4.3 respectively. In figure 2 (panel A and B) 
the presence of rFbn accelerated the rate of pFXIIIa2* formation when compared 
with that of FI. We also observed that γγ’rFbn increased the rate of pFXIIIa2* 
generation by approximately 28% when compared with that of γγ rFbn. (figure 
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2B). Statistical analysis (P value <0.05) indicated the statistical significance of 
γγ’rFbn over the γγrFbn and both γγ and γγ’ rFI (Figure 4.2C) .Surprisingly, the 
effect of γγ’rFbn over the rate of pFXIIIa2* formation was minimized when the 
thrombin cleaved dimeric subunit factor XIII A subunit (pFXIIIa2’) was incubated 
with FI or Fbn (figure 4.3B). The results presented no statistical significance 
between γγ’rFbn and γγrFbn.  Similar results were observed when γγ or γγ’ rFI 
were incubated with pFXIIIa2’ (figure 4.3C). The decrease in the OD signal is 
related to the fibrinogen fibrinopeptide release by thrombin. These results 
indicated that the pFXIII-B sub-unit enhance the rate of pFXIIIa2* formation 
which can be attributed to the interactions with the γ’ chain.  
4.4.3. The combine effect of the pFXIII-B subunit and the γγ’rFI accelerates 
pFXIIIa2b2 activation. To expand our assessment of the combine effect of the γ’ 
chain on the rate of pFXIIIa2* generation, we perform HPSEC to investigate the 
pFXIIIa2b2 dissociation. Figure 4.4 panel A shows the HPSEC chromatography 
profile of the calcium induced pFXIIIa2b2 dissociation, the γγrFI pFXIIIa2’b2 and 
the γγ’rFI pFXIIIa2’b2 in the presence of physiological calcium concentration 
(1.5mM). The pFXIIIa2b2 dissociation was promoted by the removal of APFXIII in 
30mM CaCl2. The dimeric pFXIIIa2 and pFXIIIb2 elutes as a single peak centered 
at minute 51.3 and 59.6 respectively.  
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Figure 4.4: A) HPSEC profile of: (••) pFXIIIa2’b2+rFIIa+30mMCaCl2, (--) 
pFXIIIa2’b2+γγrFI, (˗˗) pFXIIIa2’b2+γγ’rFI. Pooled fractions F1 and F2 were individually 
collected for each mixture. B) Anti factor XIII-A subunit western blot. C) Anti factor 
XIII-B subunit western blot.   
When γγrFI was mixed and incubate for 5 minutes with pFXIIIa2’b2 two 
peaks centered at minute 48.1 and 60.2 with absorbance of 3465.06 and 388.31 
mAU respectively were observed. In similar conditions and concentrations, γγ’rFI 
and pFXIIIa2’b2 were incubated for 5 minutes and loaded on the HPSEC. The 
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chromatogram profile showed the elution of two main peaks centered at minute 
47.12 and 59.63 with absorbance of 3462.50 and 706.40 mAU respectively. The 
collected fractions were analyzed by western blotting using an anti-human FXIII-
A and FXIII-B antibody. In figure 4.4 panel B, no presence of FXIII-A subunit 
was detected in all fractions 2 (F2). In the same figure, we noticed that all 
fractions 1 (F1) are mainly composed of the thrombin cleaved FXIIIA’. However 
when F1 and F2 were analyzed with FXIII-B antibody (figure 4.4 panel C), the 
presence of FXIII-B subunit was detected in both fractions. The densitometric 
analysis of the western blots indicates that the presence of γγ’ increased the 
FXIII-B subunit dissociation by about 40 % when compared to the γγ.   
To further assess the effect of γγ’rFbn and the pFXIII-B, we performed 
non-denatured SDS-Page on the mixtures of γγrFbn/pFXIIIa2b2/rFIIa and 
γγ’rFbn/pFXIIIa2b2/rFIIa. As presented in figure 4.5, densitometry analysis 
indicated that the mixture γγ’rFI-pFXIIIa2’b2 increased the rate of pFXIIIa2’b2 
dissociation by about 10% when compared with that of γγrFI-pFXIIIa2’b2. We 
also observed the formation of high molecular weight fibrin species suggesting 
the rapid formation of pFXIIIa2* which catalyzes the fibrinogen polymerization. 
As suggested by Cooke [8], we observed that the minimum calcium concentration 
to induced pFXIIIa2b2 dissociation is about 30mM (figure 4.5-lane5). In addition, 
the presence of either γγFI or γγFI induced the pFXIIIa2b2 subunit dissociation at 
physiological levels of Ca
2+
. (figure 4.5 lane 9, lane 12).  
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Figure 4.5: pFXIIIa2b2 activation SDS-PAGE gel analysis: Lane1: See Blue plus 2 
Marker, Lane 2: Reduced pFXIIIa2b2, Lane 3: Non-reduced pFXIIIa2b2 , Lane 4: 
Reduced pFXIIIa2b2 +1.1U rFIIa, Lane 5: Non-reduced pFXIIIa2b2+1.1U rFIIa+30mM 
CaCl2, Lane 6: Non-reduced pFXIIIa2b2+1.1U rFIIa+1.5 mM CaCl2, Lane 7: Non-
reduced γγrFI + pFXIIIa2b2, Lane 8: Non-reduced pFXIIIa2b2 + γγrFI + 1.1U rFIIa, Lane 
9: Non-reduced pFXIIIa2b2 + γγrFI +1.1U rFIIa+1.5mMCaCl2, Lane 10: Non-reduced 
γγ’rFI + pFXIIIa2b2, Lane 11: Non-reduced pFXIIIa2b2 + γγ’rFI + 1.1U rFIIa, Lane 12: 
Non-reduced pFXIIIa2b2 + γγ’rFI +1.1U rFIIa+1.5mMCaCl2. 
4.4.4. Estimation of kinetic constants: Michaelis-Menten (KM) and Maximal 
Velocity (Vmax). 
4.4.4.1. γγ rFI and pFXIIIa2b2 mixture. 
The results of the estimation of KM and Vmax obey to the reaction 
proposed in scheme C3. Figure 4.6A shows the linear regression of the 
Elapsed crosslink time vs Absorbance at different concentrations of the biotin 
peptide. Each linear regression equation has a correlation coefficient greater 
1     2     3      4     5      6      7    8     9     10   11    12  
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than 0.98 which validates the accuracy of the obtained data.  Table 3.1 shows 
the data used to prepare the Linewaever-burk plot (1/[S] vs 1/Vo). Figure 
4.6B, shows the Lineweaver-Burk plot. The regression coefficient was 
estimated to be 0.97. 
 
Table 4.1.: Lineweaver-Burk plot data γγ rFI and pFXIIIa2b2 mixture. 
Substrate conc. 5BAPA 
(M) 
Initial velocity 
Vo (min) 
1/S 1/Vo 
0.00025 0.0412 4000 52.6316 
0.0005 0.0358 2000 38.1679 
0.001 0.0262 1000 27.9330 
0.0025 0.019 400 24.2718 
 
y = 0.019x + 0.0573 
R² = 0.9945 
y = 0.0262x + 0.0525 
R² = 0.9948 
y = 0.0358x + 0.0543 
R² = 0.999 
y = 0.0412x + 0.0595 
R² = 0.9997 
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Figure 4.6: Estimation of KM and Vmax. γγ rFI and pFXIIIa2b2. 
4.4.4.2.KM and Vmax estimation for the γγ’ rFI and pFXIIIa2b2 mixture.  
As previously presented for the γγ rFI and pFXIIIa2b2 mixture, the KM and 
Vmax estimation for the γγ’ rFI and pFXIIIa2b2 mixture was performed 
following the same procedure. Figure 4.7A represent the elapsed crosslink 
time of the peptide incorporation reaction. Linear regression of each is 
presented in figure 4.7A. The Lineweaver-burk plot is presented in figure 
4.7B. 
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Table 4.2.: Lineweaver-Burk plot data γγ’ rFI and pFXIIIa2b2 mixture 
Substrate conc. 5BAPA 
(M) 
Initial velocity 
Vo (min) 
1/S 1/Vo 
0.00025 0.0159 4000 62.8931 
0.0005 0.0204 2000 49.0196 
0.001 0.0252 1000 39.6825 
0.0025 0.0344 400 29.0698 
 
 
Figure 4.7: Estimation of KM and Vmax. γγ’ rFI and pFXIIIa2b2. 
 Table 4.3: Estimated Vmax and KM for the mixtures: γγ  rFI + pFXIIIa2b2 and γγ’ rFI + 
pFXIIIa2b2 
Mixture 
Maximal Velocity 
(Vmax) mol/min 
Michaellis-Menten Constant 
(KM) (M) 
γγ  rFI + pFXIIIa2b2 0.044 3.27 x 10
-4
 
γγ’ rFI + pFXIIIa2b2 0.035 3.11 x 10
-4
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In table 4.3 the kinetic constant values KM and Vmax for the γγrFI+pFXIIIa2b2 and 
γγ’rFI+pFXIIIa2b2 mixtures are showed. Both mixtures present similar KM values. 
3.27x10
-4
 and 3.11x10
-4
 for the γγrFI+pFXIIIa2b2 and the γγ’rFI+pFXIIIa2b2 respectively. 
The estimated Vmax for both mixtures are 0.0454(min) and 0.0349(min) for 
γγrFI+pFXIIIa2b2 and the γγ’rFI+pFXIIIa2b2. The differences between the last values are 
in the range of hundredths and do not represent a significant difference based on the 
methodology used to estimates these values.  
4.5. Discussion 
Our analysis assumes a lack of mass transfer restrictions with respect to the supply of 
Factor XIII zymogen occurring within the immobilized fibrinogen or fibrin hydrogel 
phases. The pFXIIIa2b2 activation mechanism requires thrombin and fibrinogen/fibrin as 
cofactors. [11, 29] The stages of the pFXIIIa2b2 activation begins with the thrombin 
proteolytic removal of the factor XIII activation peptide yielding the non-active 
pFXIIIa2’b2. Consecutively, the dissociation of pFXIIIa2’b2 which is facilitated and 
enhanced by the presence of fibrin and calcium at physiological levels, yields the dimers 
pFXIIIa2’ and pFXIIIb2. In the final stage, the pFXIIIa2’ dimer undergoes conformational 
changes to expose the active cysteine site and form the active pFXIIIa2*. Although the 
pFXIIIa2b2 activation mechanism was assessed in the presence of thrombin and 
fibrinogen, the impact of the γγ and γγ’ fibrinogen and fibrin variants and the pFXIII-B 
subunit were not conclusive.  
To obtain relevant data and reconcile previous experiments, three preparations that 
resemble the main stages of the pFXIIIa2b2 activation phases were evaluated along with 
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thrombin and the two major variants of γγ and γγ’ recombinant fibrinogen / fibrin. We 
demonstrated that the presence of γγ’ fibrin increases the rate of generation of pFXIIIa2b2 
which may be related to the acceleration of the proteolytic activity of rFIIa. As previously 
suggested by Hornyak [4] the geometric disposition of the pFXIIIa2b2–fibrin–thrombin 
expedites the enzymatic activity of thrombin which accelerates the proteolytic removal of 
the APFXIII. However the fact that the γγ’ rFbn increases the rate of APFXIII cleavage may 
be related to a particular high affinity binding site located in D domains on γ’ chains as 
reported by Meh [25] suggesting the formation of termolecular complex (pFXIIIa2b2–
fibrin–thrombin). Within this context, we can also suggest that the formation of the 
termolecular complex facilitates the proteolytic cleavage of the APFXIII which is 
necessary for the posterior pFXIIIa2b2 sub-unit dissociation.  
We also demonstrated that the γγ’rFbn accelerates in about 23% the generation of 
pFXIIIa2* when compared with the γγrFbn. This increase on the pFXIIIa2* generation 
may be related to the rate of pFXIII-B subunit dissociation.  First, we suggested that the 
formation of a termolecular complex is necessary to enhance the thrombin proteolytic 
activity. In concordance with our results, we can certainly conclude that γγ’rFbn 
accelerates the pFXIIIa2* generation by inducing factorXIII-B subunit dissociation at 
faster rate than γγrFbn. As showed in figure 4.2 and 4.3, the presence of pFXII-B subunit 
plays an important role in the rate of pFXIIIa2* generation. In fact, no statistical 
difference was found when either γγ or γγ’ rFbn was incubated with pFXIIIa2’ or 
rFXIIIa1. In addition, our studies indicated that fibrinogen conversion to fibrin was not 
indispensable to induce pFXIIIa2b2 subunit dissociation. As demonstrated by our HPSEC 
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analysis, the dissociation of pFXIII-B subunit was enhanced by the presence of γγ’rFI 
when mixed with pFXIIIa2’b2. However, as shown in western blots, not all this 
dissociation wasn’t achieved at its maximum since some pFXIII-B subunit was detected 
on the fraction bound to either γγrFI or γγ’rFI. From this analysis we can suggest that 
conversion to fibrin is required to achieve the complete dissociation of pFXIII-B subunits 
from pFXIIIa2’b2. We can also concluded that the thrombin cleaved, pFXIIIa2’, binds to 
either γγrFI or γγ’rFI as shown by our HPSEC analysis in which the formation of a single 
peak is shown.  
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CHAPTER V 
Solution phase associations between Human fibronectin and fibrinogen γγ’ 
heterodimer observable using high pressure size exclusion chromatography and 
dynamic light scattering. 
5.1.Summary 
We previously reported the isolation of a binary mixture of γγ’-fibrinogen (γγ’-FI) 
and fibronectin (pFN) from human plasma that formed a novel fibrin structure with 
increased viscoelastic strength. Here we use HPSEC and DLS to characterize interactions 
between γγ’-FI and pFN occurring within that binary mixture. HPSEC fractionation 
showed distinct subpopulations having unique column residence times obtained when 
each of these subfractions were individually reprocessed by HPSEC.  The relative 
hydrodynamic sizes of these reprocessed subfractions were intermediate to that observed 
for pure γγ’-FI and pFN as measured by both HPSEC and DLS. SDS-PAGE composition 
analysis indicated that the γγ’-FI and pFN were not covalently linked as can occur due to 
Factor XIII transglutaminase activity commonly associated with γγ’-FI preparations.    
Purified pFN was mixed with purified γγ’-FI or Aα-chain deficient (des-Aα) γγ’-FI or γγ-
FI or des-Aα γγ-FI and associations between pFN and γγ’-FI or des-Aα γγ’-FI occurred 
spontaneously within 5 minutes. This was evident from the appearance of species having 
intermediate HPSEC and DLS relative hydrodynamic sizes and reduced presence of the 
original component species.  A similar behavior was not observed after the mixing of 
pFN with γγ-FI or des-Aα γγ-FI.   Previous reports were not able to observe these 
associations by SPR which immobilizes one of the species and therefore a complex 
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dependence on the freedom of motion occurring when γγ’-FI and pFN are both in 
solution is indicated.  Furthermore, the presentation of γ’ but not γ or Aα chains is 
required to catalyze this reversible process resulting in a compacted overall structure.   
5.2.Introduction 
Human fibrinogen (FI) and plasma fibronectin (pFN) are both large blood proteins 
produced by hepatocytes.  They are essential precursors to the formation of fibrin 
polymer and its dual function as an adherent hemostatic barrier and provisional matrix to 
induce healing.  pFN is incorporated directly from blood into the fibrin matrix during the 
polymerization of F1 where it augments fibrin strength.  F1 and pFN occur in human 
plasma at a ratio of about 90 F1:10 pFN.   
Solution phase interactions between F1 and pFN prior to fibrin formation have not yet 
been well elucidated.  F1 and pFN have contrasting tertiary structures.  For example, 
DLS analysis of F1 shows a narrow distribution of cylindrical structures having high 
aspect ratios.  In contrast, purified FN typically exists as a Gaussian conformation 
consisting of a string of multiple beadlike domains.  A high accessibility of 
conformationally internalized FN segments likely occurs in human plasma that imparts 
FN ligand functionality associated with solid phase binding to fibrin and extra cellular 
matrix (ECM) proteins.   
FI is a hexameric glycoprotein having an Mr of 340 kDa:  FI consists of two Aα 
(Mr=66.5 kDa), two Bβ (Mr=52.0 kDa) and two γ chains with subtly different Mr 
(Mr=46.5kDa  and  50.0kDa) which can be resolved by SDS-PAGE electrophoresis.  Its 
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cylindrical conformation arises from a disulfide bridging of these 6 chains creating a 
linear symmetry identified by two outer D domains connected to a central E domain [32, 
33].   About 10% of FI molecules possess a heterodimeric pairing of γ and γ’ chains (γγ’-
FI) and the remaining 90% are homodimeric in γ-chains (γγ-FI).  A γ-chain 
transcriptional variant results in a net replacement of 4 amino residues of the γ chain 
carboxy-terminus with a 20 aa extended γ’-carboxy terminal sequence.  Two-sulfated 
tyrosines occur within the γ’ impart a greater acidity making γγ’-FI isolatable from γγ-FI 
by DEAE chromatography [35, 36].   The physiologic role of abnormal γγ’-FI levels has 
been correlated with a complex and pleotropic impact on vascular health not observed 
with γγ-FI levels. 
Plasma FN is a disulfide linked dimer consisting of two slightly different chains 
estimated at 198 kDa and 208 kDa.  These chains are linked together at their carboxy-
terminus terminus [22] but differ in their Domain V amino acid composition.  The 
solubility of pFN distinguishes it from cellular matrix FN (cFN): cFN has a low solubility 
that leads to its incorporation into ECM soon after its secretion and that is likely due to 
the presence of an ED domain not present in pFN.  Each pFN chain consists of a linear 
arrangement of repeating units known as: type I, type II and type III which exist as 
individual globular sub-domains.  pFN contains 12 type I repeats (about 40 amino acid 
and 2 disulfide bonds), 2 type II repeats (60 amino acids and 2 intrachain disulfide) and 
15 constitutive and 2 alternative spliced type III and one variable type III. [23, 24].  Each 
repeating unit operates as distinct domain and this imparts a significant degree of chain 
flexibility [19, 20, 21]  facilitating interaction with ECM proteins like collagen and also 
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fibrin [21].  While past studies have shown that pFN contains two major fibrin binding 
sites (Fib-2) [25, 26], its interactions with whole population F1 were reported as highly 
temperature dependent and strongest at 4 
o
C  [27]. 
Our recently reported results show that in addition to the acidity of each protein, γγ’F1 
and pFN have interactions which may be contribute to their co-purification from normal 
human plasma using DEAE-chromatography.  We also observed the formation of fibrin 
matrices that were stronger than that obtained with analogous mixtures of pFN and γγF1. 
In this study we use HPSEC and DLS to observe interactions between binary mixtures of 
pFN and γγ’-F1 uniquely purified from human plasma.  Furthermore, we use 
reconstitution of purified FN with γγ-F1, or γγ’-F1 or Aα-chain deficient (des γγ’-FI) or 
des-Aα γγ-FI to study interactions between these species and unique involvement of γγ’-
FI with pFN.  
5.3.Materials and Methods 
5.3.1.Materials 
Chemicals of ACS grade were purchased from J.T. Baker (Phillipsburg, NJ) and 
Millipore-Sigma (St. Lois, MO). Human plasma was provided as a gift from the U.S. 
Army Materials Command (Fort Detrick, MD). Human plasma-derived fibrinogen (pdFI) 
depleted of plasminogen, von Willebrand factor and fibronectin was purchased from 
Enzyme Research Labs (South Bend, IN). Human fibronectin was purified from human 
plasma following a procedure previously described [41]. γγ and γγ’ fibrinogen species 
were obtained from human plasma. Species isolation was performed according to a 
proposed procedure [10] Native γγ’FI:FN mixture was isolated from human plasma as 
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recently described by Ismail et al. [40] In Brief, 15 units of human plasma were 
centrifuged at 2702 RFC and 4°C for 20 min. the precipitated was resuspended in 20mM 
Tris-Base, 55mM sodium citrate, 27mM Lysine, pH 6.8. 0.15% TNBP and 0.5% triton X-
100 was used for viral inactivation and stirred at room temperature for 1 hour. The treated 
solution was adjusted to 1M ammonium sulfate and centrifuged at 2702 RFC for 15 
minutes at 25°C. the recovered pellet was dissolved in 20mM sodium citrate, 10mM 
NaCl pH 7.4 (wash buffer). Finally, the solution was filtered and loaded into a DEAE 
Sepharose fast flow. Bound protein was eluted with a linear gradient of 0.1–1.0 M NaCl 
in 20 mM sodium citrate and pH 7.4. Further characterization experiments were carried 
out using native γγ’FI:FN dialyzed against was buffer. 
5.3.2.High Pressure Size Exclusion Chromatography (HPSEC).   
For analytical purposes two Superose 6 10/300 (GE, Lifescience) columns were 
connected in series to a Knauer (Berlin, Germany) Smartline chromatography station and 
equilibrated with 50mM Tris buffer, 115 mM NaCl, pH 7.5 maintaining ionic strength of 
0.15. Columns were loaded with 200μg of sample and isocratically eluted using 
equilibration buffer at a flow rate of 0.35 mL/min. Loaded samples were previously 
dialyzed and filtered through a 0.2 μm Pall membrane filter (Port Washington,NY) 
Effluent’s absorbance was read at 280nm and collected fractions were assayed for protein 
content by SDS-PAGE, particle size distribution and RH using a DLS instrument. 
5.3.3.Native γγ’FI:FN HPSEC procedure 
A total of 200μg dialyzed native γγ’FI:FN mixture solution was loaded into HPSEC 
columns and isocratically eluted using elution buffer (50mM TRIS, 115mM NaCl, pH 
7.5). The eluate was collected in 11 Fractions in 1.5 minutes interval. A second HPSEC 
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pass of each collected fraction was performed following the procedure described above 
and the eluate product was then analyzed by SDS-PAGE and DLS.  
5.3.4.γγFI or γγ’FI with FN mixture reconstitution HPSEC procedure 
A 1:1 stoichiometric molar concentration of either γγFI or γγ’FI were mixed with FN and 
dialyzed against 50mM TRIS, 115mM NaCl, pH 7.5 Then, the mixtures were incubated 
at 37°C for 1 hour and loaded into the HPSEC column system. The eluted fractions were 
collected every 1.5 minutes and pooled in 3 groups to characterize each section of the 
chromatogram profile. Each pooled fractions were concentrated and reloaded into 
HPSEC . Collected fraction were evaluated by SDS-PAGE and DLS. 
5.3.5.des α-γγFI or des α-γγ’FI with FN mixture reconstitution HPSEC procedure 
fibrinogen des-α populations of either γγFI and γγ’FI were mixed with FN and the 
mixture was dialyzed and incubated as described before. 200 μg of mixture was loaded to 
the HPSEC system and collected fractions were pooled to evaluate sections of the 
chromatogram profile. Concentrated pooled fractions were reloaded to the HSPSEC 
system and collected fractions analyzed by SDS-PAGE and DLS. 
5.3.6.Dynamic Light Scattering (DLS).  
The hydrodynamic radius (RH) and particle size distribution were assessed by DLS using 
the DynaPro99 Titan Instrument (Wyatt Technology, CA). In Brief, 20μL of samples 
containing 0.5 mg/mL of HPSEC native γγ’F1:FN fractions or purified γγF1, γγ’F1, FN 
or their mixture fractions were illuminated by a 830nm laser and the intensity of scattered 
light was measured by an avalanche photodiode. The fluctuations in the measured 
intensity specifies the diffusion coefficient is estimated by autocorrelation analysis and 
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the particle hydrodynamic radius is determined using the Stroke-Einsten relationship 
which assumes the uniform sphere shape of the analyzed particle. 
5.3.7.SDS PAGE gel electrophoresis and Bicinchoninic acid assay (BCA) 
Non-reduced and reduced samples of purified γγ’FI. γγFI, FN and their mixtures were 
evaluated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 
4-12% NuPage Bis-Tris pre-cast gels (Thermofisher, CA). All the gels ran for 1 hour at 
200 volts and then stained with colloidal Blue gel stain (Invitrogen, Carlsbad, CA,). Gels 
were photographed with Canon S95 digital camera, and densitometry analysis was made 
using NIH ImageJ software [42]. The BCA total protein assay (ThermoFisher Scientific, 
New York) was performed to estimate protein concentration as described [43].  
5.4.Results 
5.4.1. Characterization of native γγ’FI:FN by HPSEC and DLS  
The formation of a novel pFN wrapped fibrin structure having enhanced 
viscoelastic strength may be related to interactions that occur between pFN and γγ’-FI 
prior to fibrin formation.  Both pdFN and each F1 subpopulation are large proteins that 
have contrasting tertiary conformations which may contribute to the formation of these 
fibrin structures.  Figure 5.1a shows the HPSEC profiles of pFN, γγ’-FI and γγ-FI 
preparations studied here.  The purity and integrity of these preparations are shown by 
reduced SDS-PAGE in Figure 5.1b.  The Aα chain of either γγ-FI (lane 1) or γγ’-FI (lane 
2) has two subpopulations having an Mr centered about 62 kDa that are typical of F1. 
The Bβ chain of either γγ-FI (lane 1) or γγ’-FI (lane 2) has a predominant subpopulation 
with an Mr centered about 55 kDa. The γ chain of the γγ-FI preparation is predominant 
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and has an Mr of about 49 kDa (lane 1).  The heterodimeric nature of γγ’-FI (lane 2) 
shows an equal presence of γ and γ’ where the γ’ has an Mr that is about 1 kDa greater 
than the γ chain.  pFN is a heterodimer possessing two different domain V structures 
migrated similarly with an Mr centered at about 198 kDa (lane 3). The HPSEC profiles 
show a distinctly larger hydrodynamic size for both γγ’-FI and γγ-FI relative to pFN.  
DLS analysis of these preparations show that γγ’-FI and γγ-FI are similar in 
hydrodynamic radius at about 12 nm while pFN is much smaller at about 10 nm (Table 
1). The polydispersity of each species by DLS is also consistent with the HPSEC peak 
widths and symmetry. 
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Figure 5.1: (a) High Performance Size-Exclusion Chromatography (HPSEC) profile of 
γγ FI, γγ’FI and FN. 200μg were loaded to two 25mL pre-packed Superose 6 10/300 GL 
(GE Healthcare) columns connected in series. HPSEC instrument was operated at 0.35 
mL/min. using 50mM TRIS, 100mM NaCl pH 7.4 Buffer. 11 fractions were collected 
every 1.5 min interval (b) Reducing SDS-PAGE analysis of fibrinogen γγ, γγ’ and 
fibronectn standards. Lane M: See blue plus marker, Lane 1: γγ pdFI, Lane 2: γγ’ pdFI, 
Lane 3: FN. (c) High Performance Size-Exclusion Chromatography (HPSEC) profile of 
DEAE elution. (d) Reducing SDS-PAGE analysis of HPSEC fractions. Lane M: See blue 
plus marker, Lanes 1-11 correspond to HPSEC collected fractions 1 through 11. (e) 
Chromatography overlay profile of fractions 3 ,6, 7, 9 and 10 passed through HPSEC. 
Samples were loaded to two 25mL pre-packed Superose 6 10/300 GL (GE Healthcare) 
columns connected in series. HPSEC instrument was operated at 0.35 mL/min. using  
50mM TRIS, 100mM NaCl pH 7.4 Buffer. (f) Reducing SDS-PAGE of fractions 3,6,7, 9 
and 10 after second pass in HPSEC. Lane M: See blue marker, lane F3: fraction 3, lane 
F6: fraction 6, lane F7: fraction 7, lane F9: fraction 9, lane F10: fraction 10.   
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Table 5.1: γγ FI, γγ’ FI, FN Hydrodynamic radius (RH) measured by DLS at 25 °C. 
Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results indicate the 
mean and standard deviation of 3 independent preparations. Statistical analysis using one-
way ANOVA indicates no significant differences between RH measurements. (P<0.035, 
α=0.05) 
Species 
Hydrodynamic 
radius (RH), nm 
Polydispersity, 
(%) 
Intensity 
distribution 
(%) 
γγ FI 12.2 ± 0.3 23.8 ± 0.9 97.3 
γγ' FI 12.1 ± 0.2 23.9 ± 1.9 95.1 
FN 10.5 ± 0.2 21.9 ± 1.1 96.3 
 
Table 5.2: HPSEC retention time of γγ’ FI-FN mixture isolated from human plasma. 
Collected fractions are numbered and showed in figure 5.1b and 5.1d 
γγ' FI-FN mixture from human plasma HPSEC second fractioning  
Sample 
Retention Time 
(min) 
Sample 
Retention Time 
(min) 
Fraction 4 60.7 Fraction 4 60.7 
Fraction 6 64.1 Fraction 6 64.1 
Fraction 7 65.8 Fraction 7 65.8 
Fraction 9 69.9 Fraction 9 70.0 
Fraction 10 70.8 Fraction 10 71.1 
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Table 5.3: γγ FI, γγ’ FI, FN Hydrodynamic radius (RH) and fractions 4,6,7,9 and 10 RH 
measured by DLS at 25 °C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 
7.4. Results indicate the mean and standard deviation of 3 independent preparations. 
Statistical analysis using one-way ANOVA indicates no significant differences between 
RH measurements. (P<0.035, α=0.05) 
Species 
Hydrodynamic 
radius (RH), nm 
Polydispersity, 
(%) 
Intensity 
distribution (%) 
Fraction 4   (F4) 12.4 ± 0.2 17.9 ± 3.9 95.4 
Fraction 6   (F6) 11.8 ± 0.3 28.3 ± 2.1 84.6 
Fraction 7   (F7) 11.4 ± 0.3 29.2 ± 1.5 82.9 
Fraction 9   (F9) 11.0 ± 0.2 30.6 ± 4.1 88.0 
Fraction 10 (F10) 10.7 ± 0.5 17.9 ± 1.8 93.9 
 
Table 5.4:  OD and mass of HPSEC fractions 1 to 11.  
 
 
 
Fraction 1 Fraction 2 Fraction 3 Fraction 4 Fraction 5 Fraction 6 
OD 0.14 0.40 0.65 0.75 0.64 0.58 
Mass* 
(μg) 
5.4 15.5 25.2 29.0 24.8 22.5 
Percentage 2.7 7.8 12.7 14.7 12.5 11.4 
 
Fraction 7 Fraction 8 Fraction 9 Fraction 10 Fraction 11 
OD 0.52 0.46 0.39 0.30 0.28 
Mass* 
(μg) 
20.1 17.8 15.1 11.6 10.8 
Percentage 10.2 9.0 7.6 5.9 5.5 
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5.4.2. Characterization of reconstituted γγ’FI with FN by HPSEC and DLS 
HPSEC fractionation of a binary, plasma-derived mixture of pFN and γγ’-FI 
shows a less distinct separation between each species relative to references purified from 
that same parent mixture. (Figure 5.1c).  Appreciable amounts of pFN appear in earlier 
eluting fractions that also contain γγ’-FI (Figure 5.1d, lanes 6,7).  A minor des-α γγ’-FI 
degradation component co-emerges from the HPSEC along with pFN.  In order to assess 
the impact of chromatographic dispersion and the identity of pFN and γγ’-FI 
subpopulations having intermediate hydrodynamic sizes, we individually reprocessed 
each fraction with the HPSEC.  Surprisingly, each fraction retained its column residence 
time while having a symmetrical peak (Figure 5.1e and Table 5.2). Furthermore, DLS 
analysis confirmed the relative Rh values indicated by HPSEC behavior for each 
reprocessed fraction (Table 5.3, figure 5.1f). This suggested the possibility of pFN and 
γγ’-FI subpopulations having coincidental and intermediate hydrodynamic sizes and or an 
association between some of these species which formed a collapsed structure. A 
reprocessed fraction contained pFN and des-α γγ’-FI.  The  des-α γγ’-FI had intact Bβ, γ 
and γ’ chains.  We estimated by OD 280 nm  reprocessed Fractions 6 and 7 to be about 
20% of the total protein of the original binary mixture and consisted of pFN and γγ’-FI. 
(Table 5.4).  In order to study the potential for forming associations between pFN and 
γγ’-FI, we mixed at a 1:1 mass ratio pFN (Figure 5.2d lane 1) and γγ’-FI (Figure 5.2d 
lane 2) similarly to that observed in the original plasma-derived binary mixture from 
which they were both isolated.  Each of these preparations behaved as distinct, resolvable 
peaks when analyzed by HPSEC.   After 5 minutes of incubation at 37 
o
C, the mixture 
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was applied to the HPSEC where the emergent peak was noticeably shifted in its balance 
relative to that of the original components with no accompanying peak resolution of the 
individual components.  When fractions from this emergent peak were each individually 
reprocessed by HPSEC, they were observed to retain their original HPSEC residence 
times (Figure 5.2c Table 5.5). The intermediate residence times of  reprocessed fractions 
6, 7 and 8 contained both pFN and γγ’-FI (Figure 5.2 d).  DLS analysis of these same 
reprocessed fractions showed an intermediate Rh to that of pure pFN and γγ’-FI that is 
congruent with their relative HPSEC residence times (Table 5.6).  These results suggest 
that the shifts in residence times and merged peak behavior of the reconstituted mixture 
are likely due to formation of intermediately sized associations between pFN and γγ’-FI.  
This also indicates that these associations were collapsed structures but reversibly formed 
as they formed from pFN and γγ’-FI isolated from the original binary plasma-derived 
mixture.  
Table 5.5: HPSEC retention time of γγ’ FI and FN mixture. Collected fractions are 
numbered and showed in figure 5.3a, 3b and 3c 
γγ’ FI + FN mixture HPSEC first 
fractioning  
HPSEC second fractioning  
Sample Retention Time (min) Sample Retention Time (min) 
γγ' FI  60.5   
FN  69.8   
Fraction 3 
60.6 
Fraction 6 
60.8 
Fraction 4 64.4 Fraction 7 64.4 
Fraction 5 69.1 Fraction 8 69.0 
‘ 
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Figure 5.2: γγ’FI and FN mixture HPSEC chromatogram profile (a) Standard γγ’FI (1) 
and FN (2). (b) γγ’FI+FN mixture HPSEC chromatogram first pass. Collected fractions 
are numbered 3, 4, and 5. (c) γγ’FI+FN mixture HPSEC chromatogram overlay second 
pass. The previous collected fractions 3, 4, and 5 were concentrated and reloaded into the 
the HPSEC system. Collected fractions are numbered 6, 7, and 8 (d) SDS-PAGE analysis 
of standards and collected fractions. 
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Table 5.6: γγ’ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS at 25 
°C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results indicate the 
mean and standard deviation of 3 independent preparations. Statistical analysis using one-
way ANOVA indicates no significant differences between RH measurements. (P<0.044, 
α=0.05) 
 Species Hydrodynamic radius 
(RH), nm 
Polydispersity, 
(%) 
Intensity 
distribution 
(%) 
γγ’ FI 12.2 ± 0.3 23.8 ± 0.9 97.3 
FN 10.5 ± 0.2 21.9 ± 1.1 96.3 
Fraction 6   (6) 11.6 ± 0.5 25.3 ± 1.4 95.7 
Fraction 7   (7) 11.4 ± 0.3 13.3 ± 5.5 99.5 
Fraction 8   (8) 10.9 ± 0.3 16.2 ± 5.1 98.8 
 
5.4.3. Characterization of reconstituted Desα-γγ’FI with FN by HPSEC and DLS 
Because of the complex hexameric nature of fibrinogen and two chain pFN, we examined 
the potential for interactions with the des-α γγ’-FI degradation species that are α-chain 
deficient but still have intact Bβ, γ’ and γ chains.  We performed reconstitution 
experiments at 37 
o
C with des-α γγ’-FI and pFN (Figure 5.3b). The HPSEC residence 
time behavior of pure pFN and des-α γγ’-FI were distinct and resolvable from each other 
as was their hydrodynamic sizes analyzed by DLS  (Figure 5.3a, Table 5.7 and 5.8).  
After 5 minutes incubation, the mixture showed an emergent peak having no 
107 
 
distinguishable component peaks.  This emergent peak was fractionated and each fraction 
was reprocessed by HPSEC. (Figure 5.3c) In particular fraction 4 retained its residence 
time identity when reprocessed (Figure 5.3d: see reprocessed peak 7-lane 7 and table 5.7) 
having a composition containing strong gel signals of both pFN and des-α γγ’-FI.  DLS 
showed that this fraction also exhibited an intermediate Rh to either of the participating 
constituents (Table 5.8).   This result indicated the rapid formation of an association 
between these constituents while in the absence of α-chain.  We hypothesized that the 
presence of the γ’ was important to the interaction of the γγ’-FI with pFN and conversely 
the absence the γ’ chain in either γγ-FI or des-α γγ-FI would diminish the formation of 
interactions with pFN. 
Table 5.7: HPSEC retention time of Des-α γγ FI and FN mixture. Collected fractions are 
numbered and showed in figure 5.4a, 4b and 4c 
Des-α γγ’ FI + FN mixture HPSEC  
first fractioning  
HPSEC second fractioning  
Sample Retention Time (min) Sample Retention Time (min) 
Des-α γγ’ FI 65.6   
FN  69.8   
Fraction 3 60.7 Fraction 6 64.5 
Fraction 4 67.5 Fraction 7 67.6 
Fraction 5 69.7 Fraction 8 69.8 
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Table 5.8: Des-α γγ’ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS 
at 25 °C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results 
indicate the mean and standard deviation of 3 independent preparations. Statistical 
analysis using one-way ANOVA indicates no significant differences between RH 
measurements. (P<0.029, α=0.05) 
 Species 
Hydrodynamic 
radius (RH), nm 
Polydispersity, 
(%) 
Intensity 
distribution 
(%) 
Des-α γγ’ FI 11.7 ± 0.5 26.0 ± 2.5 95.2 
FN 10.5 ± 0.2 21.9 ± 1.1 96.3 
Fraction 6   (6) 11.4 ± 0.4 17.6 ± 1.3 97.8 
Fraction 7   (7) 11.3 ± 0.3 17.3 ± 3.3 96.0 
Fraction 8   (8) 10.9 ± 0.4 14.9 ± 2.2 99.0 
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Figure 5.3: Des-α γγ’ FI and FN mixture HPSEC chromatogram profile (a) Standard 
Des-α γγ’ FI (1) and FN (2). (b) Des-α γγ’ FI+FN mixture HPSEC chromatogram first 
pass. Collected fractions are numbered 3, 4, and 5. (c) Des-α γγ’ FI +FN mixture HPSEC 
chromatogram overlay second pass. The previous collected fractions 3, 4, and 5 were 
concentrated and reloaded into the the HPSEC system. Collected fractions are numbered 
6, 7, and 8 (d) SDS-PAGE analysis of standards and collected fractions. 
5.4.4. Characterization of reconstituted γγFI with FN by HPSEC and DLS 
We next performed analogous mixing experiments using pure pFN and γγ-FI 
(Figure 5.4) in order to deduce the potential for forming associations between these 
species.  As above, we used the same pFN (lane 2, figure 5.4d) made from the original 
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plasma-derived binary mixture having both pFN and γγ’-FI. The pure γγ-FI (lane 1, 
figure 5.4d) was made from the processing step prior to the isolation of the binary pFN 
and γγ’-FI mixture.  Prior to mixing and incubating these together at 37 oC, each of these 
preparations behaved as distinct peaks when analyzed by HPSEC (Figure 5.4a).   After 5 
minutes of incubation, the mixture was applied to the HPSEC:  unlike the pFN and γγ’-FI 
merged peak behavior, the pFN and γγ-FI were still resolvable as identifiable constituent 
peaks (Figure 5.4b). Furthermore HPSEC fractions selected from this product were each 
reprocessed by HPSEC:  each of these fractions retained their individual HPSEC 
residence times obtained prior to reprocessing (Figure 5.4c, Table 5.9).  DLS analysis of 
these same reprocessed fractions reflected Rh values more closely resembling that of the 
nearly pure γγ-FI and pFN. (Table 5.10) The composition by SDS PAGE of those 
fractions was mostly indicative of chromatographic dispersion overlap.  These results 
indicate that spontaneous formation of intermediately sized associations between pFN 
and γγ-FI did not appreciably occur relative to that of the analogous pFN and γγ’-FI 
mixture.  
Table 5.9: HPSEC retention time of γγ FI and FN mixture. Collected fractions are 
numbered and showed in figure 5.2a, 5.2b and 5.2c 
γγ FI + FN mixture HPSEC first 
fractioning  
HPSEC second fractioning  
Sample Retention Time (min) Sample Retention Time (min) 
γγ FI  60.7   
FN  69.8   
Fraction 3 60.7 Fraction 6 60.8 
Fraction 4 65.3 Fraction 7 65.5 
Fraction 5 68.7 Fraction 8 68.7 
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Figure 5.4: γγFI and FN mixture HPSEC chromatogram profile (a) Standard γγFI (1) and 
FN (2). (b) γγFI+FN mixture HPSEC chromatogram first pass. Collected fractions are 
numbered 3, 4, and 5. (c) γγFI+FN mixture HPSEC chromatogram overlay second pass. 
The previous collected fractions 3, 4, and 5 were concentrated and reloaded into the the 
HPSEC system. Collected fractions are numbered 6, 7, and 8 (d) SDS-PAGE analysis of 
standards and collected fractions. 
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Table 5.10: γγ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS at 25 
°C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results indicate the 
mean and standard deviation of 3 independent preparations. Statistical analysis using one-
way ANOVA indicates no significant differences between RH measurements. (P<0.041, 
α=0.05) 
 Species 
Hydrodynamic 
radius (RH), nm 
Polydispersity, 
(%) 
Intensity 
distribution (%) 
γγ FI (1) 12.1 ± 0.2 23.9 ± 1.9 95.1 
FN (2) 10.5 ± 0.2 21.9 ± 1.1 96.3 
Fraction 6   (6) 11.9 ± 0.6 25.0 ± 8.4 97.8 
Fraction 7   (7) 11.4 ± 0.5 26.8 ± 6.9 95.4 
Fraction 8   (8) 10.8 ± 0.3 20.5 ± 3.6 95.5 
 
5.4.5. Characterization of reconstituted Desα-γγFI with FN by HPSEC and DLS 
We performed mixing experiments using pure pFN and des-α γγ-FI in order to deduce the 
potential for forming associations between these species reflective of the absence of the 
α-chain.  As above, we used the same pFN made from the original plasma-derived binary 
mixture having both pFN and γγ’-FI where the pure des-α γγ-FI was made from the 
processing step prior to isolation of the binary pFN and γγ’-FI mixture.  Prior to mixing 
and incubating these together at 37 
o
C, each of these preparations behaved as distinct 
peaks when analyzed by HPSEC. (Figure 5.5a)  After 5 minutes of incubation, the 
mixture was applied to the HPSEC:  unlike the merged peak behavior of the pFN: des-α 
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γγ’-FI mixture, the pFN:des-α γγ-FI mixture still exhibited  resolvable constituent peaks 
(Figure 5.5b).  HPSEC fractions from this product were each reprocessed by HPSEC 
(Figure 5.5c) where the subfraction composition indicated by SDS PAGE reflected a 
greater pure components character with cross species content due to chromatographic 
dispersion.(figure 5.5d)  Each of these fractions retained their individual HPSEC 
residence times prior obtained to reprocessing (Figure 5.5c, Table 5.11).  The DLS 
analysis of these same reprocessed fractions reflected Rh more closely that of the nearly 
pure des-α γγ-FI and pFN. (table 5.12) These results indicate that spontaneous formation 
of intermediately sized associations between pFN and des-α γγ-FI did not appreciably 
occur upon mixing.  
Table 5.11: HPSEC retention time of Des-α γγ FI and FN mixture. Collected fractions 
are numbered and showed in figure 5.4a, 5.4b and 5.4c 
Des-α γγ FI + FN mixture HPSEC  
first fractioning  
HPSEC second fractioning  
Sample Retention Time (min) Sample Retention Time (min) 
Des-α γγ FI 65.6   
FN  69.8   
Fraction 3 60.7 Fraction 6 64.5 
Fraction 4 67.5 Fraction 7 67.6 
Fraction 5 69.7 Fraction 8 69.8 
 
Table 5.12: Des-α γγ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS 
at 25 °C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results 
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indicate the mean and standard deviation of 3 independent preparations. Statistical 
analysis using one-way ANOVA indicates no significant differences between RH 
measurements. (P<0.021, α=0.05) 
 Species 
Hydrodynamic 
radius (RH), nm 
Polydispersity, 
(%) 
Intensity 
distribution 
(%) 
Des-α γγ FI 11.4 ± 0.5 26.0 ± 2.5 95.2 
FN 10.5 ± 0.2 21.9 ± 1.1 96.3 
Fraction 6   (6) 11.8 ± 0.2 19.8 ± 2.1 99.0 
Fraction 7   (7) 11.5 ± 0.5 30.9 ± 7.0 89.4 
Fraction 8   (8) 10.7 ± 0.2 23.3 ± 0.6 98.3 
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Figure 5.5: Des-α γγ FI and FN mixture HPSEC chromatogram profile (a) Standard Des-
α γγ FI (1) and FN (2). (b) Des-α γγ FI+FN mixture HPSEC chromatogram first pass. 
Collected fractions are numbered 3, 4, and 5. (c) Des-α γγ FI +FN mixture HPSEC 
chromatogram overlay second pass. The previous collected fractions 3, 4, and 5 were 
concentrated and reloaded into the the HPSEC system. Collected fractions are numbered 
6, 7, and 8 (d) SDS-PAGE analysis of standards and collected fractions. 
5.5.Discussion 
The Interaction of fibrinogen with fibronectin initially observed on the formation of cold 
insoluble precipitates [27]. A later study indicated that this interaction was limited in 
fibrinogen due to the cryptically hidden αC chain which was exposed in fibrin after the 
thrombin proteolytic removal of the fibrinogen peptides [29]. However, Nagatmatsu et. 
al. used DLS to evaluate the diffusion coefficient of a FI-FN complex purified from 
plasma as a complex from patients with rheumatoid arthritis [14].  Their work indicated 
that FN flexibility contributed to the formation of a FI-FN complex that enabled the 
spatial exposure of binding sites.  The above studies were limited to whole populations 
F1 as the γγ’FI plasma F1 subspecies was not yet well studied.  We have recently 
published the purification of a γγ’FI-FN mixture using DEAE chromatography [40]. This 
study focused on the development of strong plasma derived fibrin sealants made at low 
fibrinogen concentrations. In this work, we have reported the study of interactions 
between γγ’FI and FN.  We show that a reversible formation of a compacted γγ’FI-FN 
association exists by reassembling it from FN and γγ’FI where each species was purified 
from and by disrupting the original complex. We use des-α chain γγ’FI and γγFI species 
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arising from proteolysis to show that γγ’FI-FN association is specifically catalyzed by the 
presence of the γ’ chain.  These experiments show that rapid in situ formation of 
compacted overall γγ’FI-FN structure happens even when alpha chains are not natively 
present.  The compacted structure is hydrodynamically smaller than γγ’FI alone and 
larger than FN.  
Previous studies have not reported solution phase interactions with F1 and FN. 
These studies used techniques that immobilized portions of whole F1, fibrin or FN 
molecules that we probed by the remaining species that was in solution.  Only 
associations with immobilized fibrin and fibrinogen with solution phase FN were 
reported.  For example,  SPR identified a FN high affinity segment located in fibrin αC 
chain. [29] In addition, fibrin-Sepharose coupled columns proved to bind FN with greater 
affinity than FI-Sepharose columns. [27] In both cases fibrin was immobilized to a solid 
surface restricts freedom of motion. We hypothesize that DLS observation of these 
interaction enables the complex association and resulting compacted γγ’FI-FN complex.  
This is consistent with the formation of a 1:1 FI-FN complex purified by affinity 
chromatography from heparinized plasma of patients with RA reported by Nagamatsu et. 
al. which showed that this complexation with fibrinogen and not fibrin. [14] [44, 45].  In 
addition, Nadamatsu concluded that the high flexibility of FN in solution is needed for 
the formation of a compact molecule.  Nadamatsu and our observations do not conflict 
with neither Makogonenko et al [29] nor Stathakis et al [27] findings as exposure of 
cryptic sites within fibrinogen due to its conversion to fibrin has been shown to occur 
within FN that is incorporated into fibrin matrices.  
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FN shows specific affinity toward the FI γ’ chain in the absence of the α chain. 
Although the FI α chain presence is required for the FN interaction with fibrin [29], the 
formation of insoluble CIg cryoprecipitates [27] and the cryoprecipitation of Heparin-CIg 
mixtures [28], our experiments suggested that in addition to the FI α chain the FI γ’ 
presents a binding region for FN not studied in previous studies of whole population F1. 
For example, Stathakis et. al. concluded that for the CIg-induced precipitation to occur 
the presence of the FI Aα chain was essential. In addition, in their experiments they also 
reported the necessity of fibrin-fibrinogen complexes and CIg to form insoluble 
precipitates. They showed that fractions lacking of the FI Aα chain failed to precipitate in 
the presence of CIg as well as FI fractions containing intact α chain suggesting the 
necessity of fibrin molecules with intact α chains for precipitate formation [27]. Their 
findings were further evaluated using heparin for the formation of a heparin-precipitable 
fraction of plasma. Their studies suggested the importance of the carboxyl terminal 
segment of the Aα chain for the formation of a cold precipitable complex formed of 
heparin-CIg and fibrinogen [28]. Further evidence of the involvement of the FI α chain in 
the interaction with FN was reported by Makogonenko et. al. In their experiments, they 
used SPR and ELISA to confirm the selective interaction between FN and the fibrin α 
chain and to localize the Aα221-391 segment as an important FN binding region which 
was exposed only after the fibrinogen conversion to fibrin. Indeed, in our present study 
we were able to observe and characterize the Des-α γγ’FI-FN interaction by HPSEC.  
FN induces γγ’FI conformational changes forming a compact molecule. Our study 
shows that the initial catalysis of the rapid formation of this compacted structure is 
caused by the presence of the γ’ chain.  The compactness of the final structure indicates 
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that all chains become  involved in the final wrapped structure.  Even though both FN 
and FI conformation are highly dependent on temperature, pH and ionic strength [19, 20], 
the flexible configuration of FN under physiological conditions may induce 
conformational changes in FI when interacting together. In fact, our previous DLS studies 
indicated the structural rearrangement of the native γγ’FI-FN mixture to form a compact 
molecule [40]. Here, our DLS experiment focused on the size and particle polydispersity 
assessment indicated the monomodal monodisperse behavior of the Des-α γγ’FI-FN 
mixture (SF5: %P=17.3±3.3) and differ from all the other preparations which presented 
intermediate level of polydispersity (15%<%P<30).  Our study suggests that the 
intermediate level of polydispersity produced in all other preparations but Des-α γγ’FI-
FN mixture may be generated by the FN binding to the FI α chain which generates 
different size molecules due to FN flexibility. This hypothesis is supported by our γγFI-
FN and γγ’FI-FN interactions evaluation (table 5.3 and 5.4) which suggest that the γγFI-
FN intermediate level of polydispersity (SF2: %P=26.8±6.9) arises from the FN binding 
of the FI α chain which may generates non-homogeneous distribution of structures. When 
mixed with FN, our assessment show decrease in the RH to less than that of native γγ’ FI 
suggesting the formation of a complexed molecule accommodated and enabled by the 
flexible nature of FN. 
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CHAPTER VI 
CONCLUSIONS  
The biophysical and kinetic characteristics of factor XIII, fibrinogen and fibronectin and 
these interactions were studied in this work.  This was undertaken in the context of gaining 
understanding to phenomena which may be useful to therapeutic applications of recombinant 
versions of these complex proteins that are essential for establishing a provisional polymeric 
barrier needed for regaining hemostasis and for initiating healing after tissue is wounded.  These 
proteins contribute to this important physiologic function by nanoscale material structural 
properties as a barrier to fluid loss and through cell signaling need to initiate wound healing as a 
provisional matrix. This work focuses on the molecular analysis of the interactions of these 
proteins, their enzymatic versus substrate roles and strives to visualize and further the 
conceptualization and nature of their interactions that will be useful in the future to physiologic 
manipulations as biotherapeutics.  From these studies, we  conclude the following: 
1. Consistent with past reports, our studies confirm the interaction of plasma factor XIII 
(pFXIIIA2B2) with the fibrinogen (FI) γ’ chain via the B subunit of FXIII.  We uniquely 
conform this association by a combination of molecular size measurements and also with 
kinetics observable from phenomena occurring within a fibrin or fibrinogen hydrogel 
phase immobilized on an assay surface. Importantly we have used contrasting 
interactions using a monomeric recombinant Factor XIII having only an A subunit to 
further support this conclusion.  Importantly, we newly adapted a prior published version 
of this assay to serve our kinetic observation purpose.   Our studies have resulted in the 
characterization of the underlying kinetic phenomena of fibrin cross-linking associated 
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with the monomeric, rFXIII made in Pichia pastoris and useful for use in fibrin sealant 
applications.  
2. Unlike past reports, our experiments were uniquely performed using the recombinant 
homodimer γγF1, the heterodimer γγ’ FI having no background activity of plasma factor 
XIII.  These demonstrate that the γγ’ FI subspecies of F1 is responsible for the intrinsic 
interaction via the factor XIII B subunit. The phenomena observed by size exclusion 
chromatography and confirmed by the use of Sepharose 6 column showed a greater 
affinity of  tetrameric,  plasma factor XIII (pFXIIIA2B2) towards the γγ’ FI than the γγ FI.  
Conversely, experiments also demonstrated that the pFXIIIA2B2 has a low affinity level 
related by slower kinetic processing of γγ FI as confirmed by transglutaminase mediated 
peptide incorporation assay.  The pFXIIIA2B2–FI γγ’ interaction induces structural 
rearrangements. This was suggested by dynamic light scattering (DLS) studies where the 
high level of polydispersity was observed indicative of the rearrangements induced by the 
tetrameric nature of pFXIIIA2B2.  Our studies suggest that pFXIIIA2B2 – FI γγ’ 
interaction can occur as a 1:2 molecular ratio. This conclusion suggests that one 
pFXIIIA2B2 can support two FI γγ’ possibly via the two separate FXIII B subunits. 
3. The rate of pFXIIIA2B2 activation is accelerated by the γ’ fibrin chain.  Our adapted 
incorporation peptide assay showed a faster rate of pFXIIIA2B2 activation than occurred 
in γγ FI.  Moreover, our studies indicate that the rate of factor XIII B subunit dissociation 
is catalyzed by either the fibrinogen/fibrin forms of  γγ’ FI.  This is consistent with 
previous studies that suggested the  γ’ chain acts as a cofactor facilitating the FXIII B 
subunit dissociation.  
126 
4. This work presents physical chemical evidence of the reversible interactions specifically 
between the γγ’ fibrinogen (FI) and fibronectin (FN) that lead to the formation of a 
compacted complex. Previously it was suggested that complexation was only observable 
between whole population fibrin and FN and that identified the importance of the α–chain 
for the interaction to occur.  Our studies are unique in their use of pure FI species:  γγF1,  
γγ’F1, des α-γγF1, des α-γγ’F1 and FN.  Our studies using SEC analysis of the interaction 
between each of the isolated FI species,  γγF1,  γγ’F1, des α-γγF1, des α-γγ’F1 and FN 
showed the presence of the γ’ chain was needed to initiate FN complexation.  The unique 
use of purified des-α FI γγ’, des α-γγF1 and FN enabled discernment that the absence of 
α-chain shows that γ’ chain initiates the complexation with FN.  
5. Our studies isolate an (FN)–FI complex from normal human plasma and not plasma from 
RA patients. The biophysical analysis of these molecules performed using SEC and DLS 
indicated that the molecular size did not experiment changes suggesting that the linear 
and semi-globular structure of FI and FN collapse into a wrapped structure with 
molecular size which clearly ranges between that of the hydrodynamic size FI and FN. 
